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Background: Atrial fibrillation (AF) is a common cardiac arrhythmia which confers a considerable 
risk of mortality and morbidity from thromboembolism and stroke. Patients exhibiting AF and 
coronary artery disease (CAD) with an acute coronary syndrome (ACS) or those who are undergoing 
Percutaneous Coronary Intervention (PCI) present an interesting challenge, especially since such 
patients are likely to develop cardiovascular-related mortality and morbidity. To prevent 
atherothrombotic events, oral anticoagulant therapy is provided with antiplatelet therapy as an 
auxiliary treatment in such patients. Recent studies have demonstrated that patients on triple therapy 
with a Vitamin K antagonist (VKA) regimen are at an increased risk of bleeding when compared to 
those on direct oral anticoagulant (DOAC) triple therapy. 
Aim: We aim at performing a systematic review of the literature and a meta-analysis of s randomized 
controlled trials in patients treated with DOACs in addition to antiplatelet therapy to assess the 
benefit-risk profile of this strategy. The final objective is to provide a rationale for the restriction of 
this strategy only in those with a high risk of thrombosis. 
Methods: A literature search of journal articles was conducted in 4 electronic databases. After the 
relevant study selections and extraction of the data, a random effects model was used and the 
summary statistics collected from each trial, structured around the type of treatment and the type of 
outcomes was calculated using the Mantel Haenszel Odds ratio (M-H OR). A one way sensitivity 
analysis assessed the robustness of the findings. Funnel plots were constructed to determine 
publication bias. 
Analysis: In the setting of AF and ACS/PCI, 4 studies were selected and in the setting of DOAC plus 
antiplatelet therapy vs DOAC alone in AF patients, 4 post hoc studies were selected for the statistical 
analysis. Observational studies were part of the discussion. 
Conclusion: Our meta-analysis shows that in the setting of AF patients with ACS/PCI, dual therapy of 
a DOAC plus an antiplatelet (P2Y12 inhibitor like clopidogrel) is preferable over a triple therapy 
containing aspirin. In the setting of AF with an indication for concomitant aspirin, it was shown that 
there was a statistically significant increase in both major bleeding and thromboembolic events. Due 
to the differences in the population of the recruited patients in terms of their comorbidities, the 
concomitant medications and the treatment regimens administered to them and the design of the 
clinical trials, it is advisable for a more calculated and personalised approach in treating higher risk 
AF patients with the added implementation of platelet function testing (PFT) as well. 
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anticoagulants, antiplatelet therapy 
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ACS Acute coronary syndrome 
AF Atrial fibrillation 
ASA Acetylsalicylic acid (aspirin) 
b.i.d. Bis in die (twice a day) 
BMS Bare metal stent  
CABG Coronary artery bypass grafting 
CAD Coronary artery disease 
COX Cyclo-oxygenase 
CrCl Creatinine clearance 
CYP Cytochrome P450  
DCC Direct current cardioversion 
DES Drug eluting stent  
DOAC Direct oral anticoagulant 
DTI Direct thrombin inhibitor  
ESC European Society of Cardiology 
ISTH International Society of Thrombosis and Haemostasis  
LAA Left atrial appendage 
LMWH Low molecular weight heparin 
MACE Major adverse cardiovascular event  
M-H OR Mantel-Haenszel Odds ratio 
MI Myocardial Infarction 
NA Not available 
NSTEMI Non-ST elevation myocardial infarction 
o.d. onus in die (once a day) 
PCI Percutaneous coronary intervention 
PFT Platelet function testing  
PRISMA Preferred reporting items for systematic reviews and meta-analyses 
PROBE  Prospective randomized open, blinded end-point 
SAN Sinoatrial node  
SD Standard deviation 
SE Systemic embolism  
STEMI ST-elevation myocardial infarction 
TIA Transient ischemic attack 
TIMI Thrombolysis in myocardial infarction  
TXA2 Thromboxane A2 
UFH Unfractionated heparin 




Atrial fibrillation and coronary heart disease 
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias whereas coronary 
artery disease (CAD) is the most common cardiovascular disease which is characterised by 
the atherosclerosis in the coronary arteries [1]. In patients suffering from AF, the contraction 
of the atria of the heart is irregular which causes improper relaxation of the cardiac muscle. 
Consequently, there is a decrease in the heart’s cardiac output. The abnormal firing of the 
electrical impulses in the atria causes the sinoatrial node (SAN) to lose control over the 
rhythm of the heart [2]. It is believed that AF is precipitated by the interaction between the 
initiating triggers, namely the rapidly firing ectopic foci located inside one or more 
pulmonary veins, and an abnormal atrial tissue substrate which supports the arrhythmia [3]. 
As a result, AF promotes the stasis of blood, paving the way for thrombus formation and 
subsequently causing emboli. This blood stagnation can be attributed to the reduced blood 
flow and diminished contractility of the left atrial appendage (LAA) [4]. Due to the 
thromboembolism, there is a significant risk of mortality and morbidity in this population. 
This risk is found to be similar among patients with paroxysmal, persistent, or permanent AF 
[5]. In paroxysmal AF, the occurrence of AF is usually self-limiting (within 7 days). In 
persistent AF, it is present for longer than 7 days and which would require cardioversion for 
ceasing the arrhythmia, either with drugs or by direct current cardioversion (DCC). 
Permanent AF exists when the arrhythmia has been present for more than 1 year [6]. In some 
patients, both paroxysmal and permanent AF might progress to become a permanent AF. 
Preventing stroke is critical in the management of such patients. Ischemic stroke arising from 
AF was found to be more fatal than non AF stroke [7]. CHA2DS2-VASc score is a clinical 
risk assessment tool recommended by the European Society of Cardiology (ESC) to be used 
to predict the risk of stroke and systemic embolism in AF patients. In this composite score, 
patients with congestive heart failure, hypertension, diabetes, vascular disease, age 65–74, 
and those belonging to the female sex are given a score of 1 for each corresponding risk 
factor whereas those with age ≥ 75 and a prior stroke or transient ischemic attack (TIA) or 
arterial thromboembolism, the score is doubled for the accompanying risk factor [8]. 
Likewise, the HAS-BLED score is used to predict the risk of bleeding in these patients. 
Acute coronary syndrome (ACS), a subcategory of CAD, is characterised by ST elevation 
myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) or 
unstable angina. CAD is typically asymptomatic while ACS almost always presents with a 
symptom, such as unstable angina, and is often linked with myocardial infarction (MI) 
irrespective of the presence of CAD [9, 10]. Many of the clinical manifestations of ACS are 
triggered by atherosclerotic plaque rupture of the affected coronary artery with the exposure 
of the thrombogenic lipid core to the blood flow causing luminal thrombosis [11]. The risk of 
ischemic events like MI and stroke is associated with major bleeding in these patients [12]. 
Though the prevalence of CAD in AF patients is around 17% to 46.5%, the prevalence of AF 
in those with CAD is just around 0.2% to 5% [1]. However, the incidence of new onset AF is 
increased in ACS patients especially in those presenting with severe complications [13]. 
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More than 80% of AF patients with associated cardiovascular disease are advised for oral 
anticoagulation and around 20% of them requiring percutaneous coronary interventions (PCI) 
over time [14]. Patients with AF are found to develop thrombi which are rich in fibrin when 
compared to patients with CAD who develop thrombi which are rich in platelets [15]. Almost 
all of these patients are indicated continuous oral anticoagulation and adjunct treatment with 
antiplatelet agents, either a single antiplatelet therapy or dual antiplatelet therapy [16]. The 
type of antiplatelet could be either aspirin or a P2Y12 inhibitor like clopidogrel or the newer 
P2Y12 inhibitors like prasugrel or ticagrelor which primarily target at the stages of platelet 
activation and aggregation. As a matter of course, vitamin K antagonists (VKA) like warfarin 
had remained as the anticoagulant of choice for stroke prevention in AF patients. However, 
with the advent of the newer direct oral anticoagulants (DOACs), the role of warfarin 
especially in the context of non-valvular AF is being redefined. 
As with the use of any antithrombotic drugs, clinicians need to consider the risks of ischemic 
stroke and thromboembolism, recurrent cardiac ischemia or myocardial infarction (MI) 
and/or stent thrombosis, with that of bleeding. Increase in the risk of bleeding in such patients 
increase the risk of mortality as well [17]. Among the OACs of choice in the setting of AF 
patients with ACS or those undergoing PCI, DOACs have shown to reduce mortality 
significantly by at least 11% to 12%, stroke and systemic embolism by 18% to 23%, and also 
intracranial haemorrhage by 21% to 54% compared to warfarin [18]. Also, since some 
DOACs have demonstrated their efficacy in the prevention of ischemic events in patients 
with only ACS [19], the question of whether additional antiplatelet therapy in AF patients 
with ACS or those undergoing PCI is required arose. Usually, during the first year after a 
cardiac ischemic event, dual antiplatelet therapy is used to prevent stent thrombosis [20]. 
 
VKA vs DOACs 
VKAs like warfarin work by decreasing the K-dependent γ-carboxylation of clotting factors 
II, VII, IX, and X but also inhibit the synthesis of some endogenous anticoagulants, proteins 
C and S [21]. The superiority of warfarin over antiplatelet therapies alone for AF was 
demonstrated in the ACTIVE W trial [22]. Dual antiplatelet therapy, by itself, is not 
sufficient to provide adequate protection against stroke associated with AF [23, 24]. 
However, the use of VKAs has many drawbacks, mainly involving the need to ensure good 
anticoagulation control and drug interactions [25]. As such, in a clinical environment, 
managing AF patients is difficult owing to the required drug dose adjustments wherein the 
suboptimal management of therapy with VKAs can lead to a lesser efficacy of the 
anticoagulant. The incidence of stroke can be reduced with an efficient oral anticoagulation 
[26]. Also, for those who have undergone PCI, it is not known to prevent stent thrombosis 
[22, 27]. Additionally, there is a high risk of bleeding with the use of both VKA and dual 
antiplatelet therapy together [28]. Increased bleeding events associated with the triple therapy 
of VKA can interrupt the treatment, thereby putting the patient at risk of ischemic 
complications [29]. Due to these disadvantages, the newer generation of anticoagulants, the 
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DOACs which do not require close monitoring and present a predictable dose response have 
found to be attractive alternatives in these scenarios. 
 
Direct thrombin inhibitor 
Dabigatran etexilate 
Dabigatran is a synthetic reversible direct thrombin inhibitor (DTI). It reversibly binds to the 
active site on the thrombin molecule, preventing thrombin-mediated activation of coagulation 
factors [30]. Since dabigatran, by itself is not lipophilic, its prodrug form (dabigatran 
etexilate) is provided for oral administration [31]. For AF patients, two doses of dabigatran 
are available: dabigatran etexilate 110 mg and dabigatran etexilate 150 mg. It is not 
influenced by cytochrome P450 (CYP) metabolism. Concomitant administration of p-gp 
inhibitors (such as amiodarone, verapamil, quinidine, ketoconazole, dronedarone, 
clarithromycin and ticagrelor) results in increased dabigatran plasma concentrations. It has a 
relatively longer half-life compared to the factor Xa inhibitors but has poor protein binding 
when compared with the same. The renal excretion is responsible for almost 80% of the total 
clearance of dabigatran . As such, dose adjustment is advised for those with an impaired renal 
clearance: 75 mg b.i.d for those with creatinine clearance (CrCl) 15 - 30mL/min [32]. 
 
Direct factor Xa inhibitors 
Unlike the indirect factor Xa inhibitors like unfractionated heparin (UFH), low molecular 
weight heparin (LMWH), and fondaparinux, which have to attach to antithrombin for the 
initiation of their  anticoagulant activity, direct factor Xa inhibitors like rivaroxaban , 
apixaban and edoxaban do not have to interact with antithrombin but can bind to both soluble 
and clot bound factor Xa [33]. The bioavailability of these types of DOACs is higher in 
comparison to dabigatran. 
Rivaroxaban 
The coagulation factor Xa  promotes thrombin generation by catalysing the cleavage of 
prothrombin [34]. Rivaroxaban inhibits factor Xa in a concentration-dependent manner and it 
is a competitive inhibitor of the amidolytic activity of factor Xa [35]. It has a half-life of 
approximately 12 hours. Potent inhibitors of CYP3A4 and P-glycoprotein diminish the 
clearance of rivaroxaban. Drugs that could alter the gastric pH have no effect on the 
pharmacokinetics of rivaroxaban. It exhibits high protein binding and so, inversely has a low 
renal clearance (around 35%). Due to its high binding affinity, a dosing of once a day is 
sufficient. Normally, it is around 20 mg o.d. Those with a moderate renal impairment (CrCl 




Apixaban is selective for factor Xa, with no impact on activated protein C, factor IXa, factor 
VIIa, or thrombin [36]. It has a mean half-life of 12.7 hours [32]. Apixaban is metabolized in 
the liver mainly by CYP3A4/5 with minor contributions from CYP1A2 and CYP2J2 [37]. 
Just like rivaroxaban, CYP3A4 and P-glycoprotein inhibitors reduce its clearance, is highly 
protein bound (around 87%) and has low renal clearance. It is excreted majorly through the 
hepatobiliary route (around 50%). Dosing of apixaban for patients is 5 mg b.i.d and a lower 
dose of 2.5 mg is recommended for the elderly (age > 80 years), those with a decrease in 
body weight ( <60 kg), serum creatinine concentrations  ≥ 1.5 mg/dL, or users of strong 
CYP3A4 and P-gp inhibitors. Renal impairment has no effect on the maximum serum 
concentration of apixaban [38]. 
 
Edoxaban 
Edoxaban competitively inhibits factor Xa directly without needing antithrombin and factor 
Xa in the prothrombinase complex. It is administered as edoxaban tosylate. It has a half-life 
of around 9-10 hours. Less than 4% of the total edoxaban dose is metabolised by the CYP450 
system, mainly CYP3A4. Similar to apixaban, it is eliminated mainly through the 
hepatobiliary route (60%) and to a lesser extent through urine (35%). It has a protein binding 
affinity of around 55%. Recommended dosing is 60 mg o.d. and the dose is reduced to 30 mg 






Aspirin (Acetylsalicylic acid)  
Thromboxane A2 (TXA2) is implicated in promoting platelet aggregation. Aspirin is an 
irreversible inhibitor of cyclo-oxygenase (COX) -1; therefore it contributes in suppressing the 
synthesis of TXA2 even at lower doses (around 75 mg/day) and at higher doses inhibits 
COX-2 [39]. During the absorption phase, aspirin is partly hydrolysed to salicylic acid after 
oral administration. Salicylic acid is eliminated by renal excretion and by metabolic 
conversion to conjugates with glycine and glucuronic acid, respectively. The half-life of 
aspirin is dose dependent. Contrary to its anticoagulant counterparts, aspirin is inefficacious 
in the prevention of thromboembolism in patients with non-valvular AF. It has been shown 
that oral anticoagulants (both VKAs and DOACs) are superior to aspirin in preventing 





Clopidogrel is a second-generation thienopyridine. It is a prodrug which is converted into its 
active metabolite by the mediation of the cytochrome P450 (CYP) enzymes [41]. It has a 
more rapid onset of action and a dosing regimen which requires the uptake of the drug once 
daily [42]. The half-life of clopidogrel is approximately 6-7 hours. Studies have demonstrated 
that in AF patients, there was a significant reduction in the aggregation of platelets with the 
combined use of clopidogrel and aspirin when compared to the use of aspirin alone [43, 44]. 
The irreversible binding of clopidogrel to P2Y12, a subtype of the adenosine diphosphate 
(ADP) receptor, on the surface of platelets prevents their aggregation. It has been shown that 
there is increased bleeding and cardiovascular events in elderly patients and also those who 
also have associated comorbidities like diabetes mellitus with the use of clopidogrel and 
therefore, caution should be exercised in such patients while administering this medication 
[45]. The activation of clopidogrel is mainly through cytochrome P450 enzymes, including 
CYP2C19. At present, clopidogrel is the standard P2Y12 inhibitor used in the setting of AF 
and ACS  patients. 
Ticagrelor 
Ticagrelor is a reversible noncompetitive, direct-acting P2Y12-receptor antagonist. The onset 
of action of ticagrelor is much faster and it is more potent than clopidogrel. Since it is not a 
prodrug, it does not require any metabolic activation for its antiplatelet effects to take place 
[46]. Though the safety of the drug is not affected by renal impairment, patients with mild 
hepatic impairment do exhibit slightly elevated levels of both ticagrelor and its active 
metabolite but without any profound adverse effect on them. There is evidence which shows 
that it improves the clinical outcomes specifically in ACS patients when compared to 
clopidogrel [47]. 
Prasugrel 
Like clopidogrel, prasugrel is a prodrug which is also an irreversible antagonist of P2Y12 
ADP receptors. But unlike clopidogrel, it perhaps has lower susceptibility to genetic 
variations and drug-drug interactions, namely with the inducers or inhibitors of cytochrome 
P450 enzymes [78]. It is metabolised by the carboxylesterase (CES) enzymes: CES1 in the 
liver and CES2 in the intestines [65]. 
 
It should be noted that in this review, we have discussed only those DOACs and antiplatelet 





The aims of this systematic review are to determine and review what will be the best strategy 
to apply for patients with AF suffering from ACS or those undergoing PCI: either the use of 
triple therapy or dual therapy. Second, we aim at assessing if add-on antiplatelet therapy on 
top of DOACs in AF patients is a requirement. Indeed, in order to prevent atherothrombotic 
events, anti-platelet therapy is often administered as an adjunct to anticoagulant therapy, 
thereby increasing the risk of bleeding in these patients. So, the question then arises to know 
if this additional anti-platelet therapy is required and if anticoagulant therapy may be 
sufficient. In this review, atrial fibrillation refers to non-valvular AF exclusively. 
Eligibility criteria 
Studies which were to be included in the review needed to have study arms where AF 
patients indicated for DOAC and concomitant antiplatelet therapy [single antiplatelet or dual 
antiplatelet] for ACS and/or undergoing PCI or for whom there is an indication for a 
combination therapy. Studies involving patients with central venous catheterization and/ or 
undergoing electrical cardioversion were excluded. 
Literature search 
We performed a systematic review and meta-analysis following the PRISMA (Preferred 
Reporting Items for Systematic reviews and Meta-Analyses) statement. Figure 1 showcases 
the PRISMA flowchart. A literature search of journal articles was conducted in the following 
electronic databases - PubMed, Scopus and the Cochrane database and also in the trial 
register – clinicaltrials.gov. The search was carried out from 2009 through October 30, 2019. 
The following search and MeSH terms, but not limited to, were used in our search strategy ‘ 
atrial fibrillation ‘ OR ‘acute coronary syndrome’ OR ‘coronary heart disease’ OR 
‘percutaneous coronary intervention’ AND ‘rivaroxaban’ OR  ‘dabigatran etexilate’ 
OR  ‘apixaban’ OR ‘edoxaban’ AND ‘platelet aggregation inhibitors’ OR ‘aspirin’ OR 
‘clopidogrel’ OR ‘ticagrelor’ OR ‘prasugrel’. The complete search strategy for the systematic 
review can be found in the Supplementary appendix. Only English-language publications 
were considered. Cohort studies will not be included in the meta-analysis since the effect 
sizes in these studies are affected by confounders as they can vary from one study to the next. 
Outcomes of interest 
The primary safety outcomes are bleeding [major bleeding, minor bleeding, clinically 
relevant non-major bleeding, any bleed, and total bleed]. As some studies employ the use of 
Thrombolysis in Myocardial Infarction (TIMI) or the International Society of Thrombosis 
and Haemostasis (ISTH) criteria to classify the bleeding outcomes, these scores were 
considered as well. The secondary efficacy outcomes were the individual and the composite 





The title and abstract screening were performed by two reviewers (G.V And H.H). Full-text 
screening and data extraction were performed by one reviewer (G.V). Discrepancies arising 
in the review process were resolved by the third reviewer (J.D). A standardized data 
extraction form was used and the meta-analysis was executed using the software package 
Comprehensive Meta-Analysis V3. This software permits to compute the desired effect size 
data in different formats published in studies, thereby allowing multivariate analyses of effect 
sizes at different time points. 
 
Quality assessment of the randomized trials 
To confirm the validity of the included randomized trials, the reviewers will assess the 
quality of the individual studies using a validated scale (Jadad scale) based on the following 
criteria: the randomization sequence generation, the method of double blinding, and status of 
the patients in the trials (withdrawals and dropouts). One point is allocated for each criterion 
satisfied and one additional point for high quality of randomization and double blinding. The 
maximum points which can be obtained are 5 points. A study will be considered high quality 
if the score is > 2 and studies with a score ≤ 2 points will be considered low quality. 
 
Statistical Analyses 
The data will be obtained from the relevant studies using summary statistics collected from 
each trial, structured around the type of treatment and the type of outcomes. A random-effect 
model will be utilised since it would be improbable that all the studies were functionally 
identical. This model considers that the results could differ from one study to another. The 
approaches of these analyses are to breakdown the observed differences into the within-
studies and the between-studies variance and then use both the components when assigning 
the weights. The summaries of treatment effects are provided by calculating the Mantel 
Haenszel Odds ratio (M-H OR) for each study. Forest plots will be constructed to view the 
treatment effects. To evaluate the stability of the results, a one-way sensitivity analyses will 
be performed by removing individual studies, one at a time. Any publication bias will be 








A total of 2227 studies were included for screening from the different databases [Pubmed: 
773 articles, Scopus : 787 articles, Cochrane database : 405 articles, Clinicaltrials.gov: 141 
studies], Eleven articles were included out of which 9 were randomised controlled trials, 1 
sub-analysis of an randomised controlled trial and 1 cohort study (➤ Figure 1). Among the 
randomised controlled trials in the setting of AF and ACS or undergoing PCI, 4 studies were 
included namely: 
• The Randomized Evaluation of Dual Antithrombotic Therapy with Non valvular 
Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (RE-DUAL PCI) 
trial [48]. In addition, a separate meta-analysis is performed for a sub-analysis of the 
RE-DUAL PCI trial based on the antiplatelet agents used namely clopidogrel and 
ticagrelor [49] 
• The Open-label, Randomized, Controlled, Multicenter Study Exploring Two 
Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist 
Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous 
Coronary Intervention (PIONEER AF-PCI) trial [50] 
• The Open-label, 2 × 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate 
the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in 
Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous 
Coronary Intervention (AUGUSTUS) trial [51] 
• The Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after 
successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI) 
trial [52]. However, for the meta-analysis, the data from the ENTRUST-AF PCI trial 
will not be considered as the patients were not assigned to a triple therapy arm of 
edoxaban. 
In the setting of AF patients who were administered a DOAC with or without a concomitant 
antiplatelet, 4 randomised controlled trials were included namely: 
• The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY trial) 
[53] 
• The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 
Fibrillation (ARISTOTLE) trial [54] 
• The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With 
Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation (ROCKET-AF) trial [55]  
• The Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–




 Data were obtained from the sub-analysis of these 4 trials. An observational study using the 
data from the DIRECT registry in Japan, where AF patients on DOAC either with or without 
antiplatelets, was included as well [57]. 
 
The AFIRE study (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With 
Stable Coronary Artery Disease) [58] will be discussed as well as it could not be included in 
our analysis based on our inclusion criteria. In this trial, AF patients were recruited if they 
underwent PCI or coronary artery bypass grafting (CABG) more than a year ago and where a 
reduced dose of rivaroxaban (15 mg or 10 mg) was preferred instead of the standard dose of 
20 mg for AF and as such, it was not considered for both the settings. 
 
Study and patient characteristics 
 
➤ Table 1 provides the design and the durations of the randomised controlled trials and the 
cohort study, the treatment arms considered for the analysis, the safety and the efficacy 
outcomes and the Jadad score the included studies. 
 
➤ Table 2 provides the baseline characteristics of patients in randomised controlled trials of 
AF with ACS/PCI. For the meta-analysis in this setting, a total of 5,468 patients were 
included from dabigatran etexilate, rivaroxaban and apixaban regimens with 751 patients of 
the edoxaban regimen from the ENTRUST-AF PCI trial analysed for discussion. 1862 
patients were allocated in both the triple therapy and dual therapy arms of the PIONEER AF-
PCI and AUGUSTUS trials. The REDUAL –PCI trial had 763 patients in the higher dose (i.e. 
dabigatran etexilate 150 b.i.d) and 981 patients in the lower dose (i.e. dabigatran etexilate 110 
b.i.d) arms of dabigatran etexilate. In the REDUAL-PCI, patients were randomized in a 1:1:1 
ratio to either dabigatran etexilate 110 dual therapy [dabigatran 110 mg twice daily (b.i.d) 
plus a P2Y12 inhibitor (either clopidogrel or ticagrelor)] ; dabigatran etexilate 150 dual 
therapy [dabigatran 150 mg b.i.d plus either clopidogrel or ticagrelor] ; or warfarin triple-
therapy [warfarin plus either clopidogrel or ticagrelor, and aspirin (≤100 mg)]. However, 
prasugrel was not considered as an antiplatelet agent. In the PIONEER AF-PCI, patients were 
allocated in a 1:1:1 ratio as well. For group 1, low-dose rivaroxaban - 15 mg once daily (o.d.) 
plus a P2Y12 inhibitor for 12 months; for group 2, very-low-dose rivaroxaban - 2.5 mg b.i.d 
plus dual antiplatelet therapy for 1, 6, or 12 months. For group 3, standard therapy with a 
dose adjusted VKA (o.d.) plus dual antiplatelet therapy for 1, 6, or 12 months. In the 
AUGUSTUS trial, patients’ stratification was based on a two-by-two factorial design where 
those planning to take a P2Y12 inhibitor were to receive apixaban (5 mg) or a VKA and to 
receive aspirin or matching placebo for 6 months. In the ENTRUST-AF PCI trial, patients 
were assigned to either edoxaban (60 mg o.d.) plus a P2Y12 inhibitor for a period of 12 
 15 
months or a VKA with a P2Y12 inhibitor and aspirin (100 mg o.d. for 1–12 months). Patients 


















Figure 1: PRISMA flowchart  
 
Altogether, the mean age of the recruited patients varied around 70 years of age. Females 
accounted for around 24% to 30 % of the total patients with the rest being males. Majority of 
these patients (both males and females included) were suffering from paroxysmal AF (around 
45% to 54%). 
 
➤ Table 3 provides the baseline characteristics of AF patients in randomized controlled 
trials of DOACs with or without concomitant antiplatelet therapy. In this setting, a total of 
48,216 patients were included for the meta-analysis. Among them, 14,357 patients were 
allocated in the DOAC plus adjunct antiplatelet therapy and 33,859 patients in DOAC alone. 
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679 duplicates 
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etexilate 150 mg were compared against warfarin. The trial demonstrated that dabigatran 
etexilate 150 mg b.i.d was superior and dabigatran etexilate 110 mg b.i.d was noninferior to 
warfarin in preventing stroke and SE in patients with AF [59]. Additionally, a subset of 
patients was receiving antiplatelet drugs at some time during the trial. Out of the antiplatelet 
drugs provided, many of them were confined to median doses of  aspirin with a few on 
aspirin ≥ 300 mg (1.6 %) , clopidogrel (1.9%) or both (i.e. dual antiplatelet therapy; 4.5%). 
Similarly, in the ROCKET-AF trial, rivaroxaban 20 mg o.d. was noninferior to warfarin [60], 
in the ARISTOTLE trial, apixaban 5 mg b.i.d was superior to warfarin [61], and in the 
ENGAGE AF-TIMI 48 trial, edoxaban (both 30 and 60 mg o.d.) were non-inferior to 
warfarin with respect to the prevention of stroke or SE in AF patients [62]. In these 3 trials, 
only single antiplatelet therapy was allowed. Aspirin was the only antiplatelet allowed in 
ROCKET-AF (< 100 mg) and ARISTOTLE (≤ 165 mg) trials. The ENGAGE AF-TIMI 48 
trial, like the RE-LY trial, had a minority of patients indicated for clopidorel (7.9%). As 
opposed to the trials of AF and ACS / PCI, P2Y12 inhibitors like prasugrel and ticagrelor 
were not used in these trials. Both the RE-LY and the ENGAGE AF TIMI 48 trials had a 
larger percentage of patients with paroxysmal AF, CAD and prior MI placed in the 
antiplatelet group whereas a similarly large percentage of permanent AF were placed in the 
group where concomitant antiplatelet therapy was omitted. 
 
➤ Table 4 provides the baseline characteristics of patients of an observational study from the 
DIRECT registry. Here, a total of 1739 patients were on any one of the DOAC regimen with 
477 patients on DOAC and either a single antiplatelet therapy or dual antiplatelet therapy. 
Abbreviations- ACS: acute coronary syndrome; AF: atrial fibrillation; ASA: acetylsalicylic acid (aspirin); b.i.d: bis in die (twice a day); DOAC: direct oral anticoagulant; MACE: major 
adverse cardiovascular events; o.d: once a day; PCI: percutaneous coronary intervention; PROBE: prospective randomized open, blinded end-point 
 







score Safety Efficacy 
AF with ACS / PCI 
NCT02415400 
(AUGUSTUS) 





apixaban  5 mg / 2.5mg   
 +  
P2Y12 inhibitor 
+ ASA 81mg 
apixaban  5 mg / 2.5 mg  
+ 
 P2Y12 inhibitor 
 







dabigatran etexilate 150 mg 
+ 
 clopidogrel 75 mg o.d. / ticagrelor 90 mg b.i.d 
dabigatran etexilate 110 mg  
+ 
clopidogrel 75 mg o.d. / ticagrelor 90 
mg b.i.d 
14 months 3 
NCT01830543 





rivaroxaban 2.5 mg b.i.d  
 (1 or 6 months ), 
 later rivaroxaban 15 mg o.d.  
+ 
ASA 75 - 100 mg o.d.  
+ 
clopidogrel 75 mg o.d. / prasugrel 10 mg o.d. / 
 ticagrelor 90 mg b.i.d ,  
later ASA 75 to 100 mg o.d. 
rivaroxaban 15 mg o.d.  
+ 
clopidogrel 75 mg o.d. / prasugrel 10 
mg o.d. / ticagrelor 90 mg b.i.d 
 
12 months 2 
NCT02866175 





edoxaban (60 mg o.d.) + 
clopidogrel 75 mg o.d. or  prasugrel 5mg/10 mg o.d. 
or ticagrelor 90 mg b.i.d 
12 months 3 








dabigatran etexilate 110 mg (b.i.d) + 
ASA/clopidogrel 
dabigatran etexilate 110 mg 
(b.i.d) 
2 years 3 
dabigatran etexilate 150 mg (b.i.d) + 
ASA/clopidogrel 








apixaban 5 mg (b.i.d) 
+ ASA ( ≤ 165 mg daily) 
apixaban 5 mg 20 months 4 
NCT00403767 
(ROCKET AF) 




rivaroxaban 20 mg o.d. 
+ ASA (mean = 99.2 mg)  








edoxaban 30 mg 
+ ASA o.d. / clopidogrel 75 mg o.d. 
edoxaban 30 mg 
2.8 years 5 
edoxaban 60 mg 
+ ASA  o.d. / clopidogrel 75 mg o.d. 








MACE DOAC + Single antiplatelet / Dual antiplatelet DOAC 
407.2 ± 
388.3 days 
   -  
18 
 
Abbreviations- AF: atrial fibrillation; ACS: acute coronary syndrome; CrCl: creatinine clearance, DOAC: direct oral anticoagulant; DE: dabigatran etexilate; MI: myocardial infarction; 
NA: not available, SD: standard deviation. Note: As per the published data , the baseline characteristics from the apixaban regimen has been extracted based on the arm, not on the 
combination of antiplatelet therapy received (no – male, female, ACS, history of stroke, type of antiplatelet used.) 
 








ENTRUST-AF PCI (2019) 
DOAC Rivaroxaban Dabigatran etexilate Apixaban Edoxaban 
Type of therapy Triple therapy Dual therapy 
DE 150 
(Dual therapy) 
DE 110  
(Dual therapy) 
Triple therapy Dual therapy Edo (60&30) [Dual therapy] 
Sample size- no./ total 709 709 763 981 1153 / 2306 1153 / 2306 751 
Age - mean ± SD 
*Median (interquartile) 
70.0 ± 9.1 70.4 ± 9.1 68.6 ± 7.7 71.5 ± 8.9 
70.8 * 
(64.4 – 77.3) 
70.4 * 
(64.1 – 77.2) 
69 * 
(63 - 77) 
Female - no. (%) 174 (24.5%) 181 (25.5%) 171 (22.4%) 253 (25.7%) 670 /2306 (29.1%) 696 /2306 (30.2%) 194 (26%) 
Male - no. (%) 535 (75.5%) 525 (74%) 592 (77.6%) 728 (74.2%) 1636 / 2306 (70.9%) 1611 / 2306 (69.8%) 557(74%) 
HAS-BLED score NA NA 2.6 ± 0.7 2.7 ± 0.7 2.9 ± 1.0 2.8 ± 0.9 3.0 (2.0-3.0 ) 
CHA2DS2-VASc score NA NA 3.3 ± 1.5 3.7  ±1.6 3.9± 1.6 3.9 ± 1.6 4.0 (3.0-5.0) 











Paroxysmal - no. (%) 325 (45.8%) 300 (42.4) 380 (49.8%) 487 (49.6%) 
1145 1145 
402 (54%) 
Persistent - no. (%) 146 (20.6%) 146(20.6%) 132(17.3%) 174(17.7%) 140(19%) 
Permanent - no. (%) 238 (33.6%) 262 (37.0%) 250 (32.8%) 320 (32.6%) 209 (28%) 





1420 / 2306 
(61.8%) 





















297 / 2289 
(13.0%) 

















































2105 / 2253 
(93.4%) 













121 / 2253 
(5.4%) 










27 / 2253 
(1.2%) 







Drug eluting stents - no. (%) 
471 / 705 
(66.8%) 
464 / 709 
(65.4%) 
621 / 762 
(81.5%) 
804 / 979 
(82.1%) 




Bare metal stents - no. (%) 
220 / 705 
(31.2%) 
231 / 709 
(32.6%) 
123 / 762 
(16.1%) 
148 / 979 
(15.1%) 
NA 
Drug-eluting & bare-metal 
stents - no. (%) 
14 / 705 
(2.0%) 
14 / 709 
(2.0%) 
10 / 762 
(1.3%) 





Abbreviations- AF: atrial fibrillation; APT: antiplatelet therapy; CAD: coronary artery disease; CI: confidence interval; DE: dabigatran etexilate; MI: myocardial infarction; NA: not 
available, SAPT: single antiplatelet therapy, SD: standard deviation. 
Note: As per the published data, the baseline characteristics from the apixaban and rivaroxaban regimens have been extracted based on the arms, not on the type of APT received  (no – male, 




Table 3 : Baseline characteristics of  AF patients in  randomised controlled trials  of DOACs with or without concomitant antiplatelet therapy 
 
Study RE-LY ARISTOTLE ROCKET AF ENGAGE AF TIMI 48 
DOAC Dabigatran etexilate Apixaban Rivaroxaban Edoxaban  (E30 & E60) 
Type of therapy DE110 +APT DE110 DE150 +APT DE150 ASA No ASA ASA No ASA SAPT No SAPT 
Sample size - no./ total 2322 3693 2304 3772 2233 / 4434 6852 / 13699 2586 / 5205 4545 / 9059 4912 14997 
Age  -  Mean ± SD 
*Median (interquartile) 





Female— no(%) 763 (32.9%) 1387 (37.5%) 765 (33.2%) 1471 (39%) 




2011 / 5205 
(38.64%) 





Male — no. (%) 1559 (67.1%) 2306 (62.4%) 1539 (66.8%) 2301 (61.0%) 




3194 / 5205 
(61.36%) 
5410 / 9059 
(59.72%) 




Paroxysmal- no.(%) 906 (39.0%) 1023 (27.7%) 915 (39.7%) 1063 (28.2%) 
707 / 4434 
(15.9%) 
2066  / 13699 
(15.1%) 
1024 / 5205 
(20%) 
1490 / 9059 
(16%) 
1510 (30.8%) 3530 (23.5%) 
Persistent - no. (%) 763 (32.9%) 1187 (32.1%) 719 (31.2%) 1190 (31.5%) 
3727 / 4434 
(84.1%) 
11630 /13699  
(84.9%) 
4090 / 5205 
(79%) 
7458 / 9059 
(82%) 
1211 (24.7%) 3376 (22.5%) 
Permanent- no. (%) 652 (28.1%) 1480 (40.1%) 669 (29.0%) 1519 (40.3%) 2189 (44.6%) 8089 (53.9%) 
 










2264 / 4434 
(51.1%) 




NA 2403 (48.9%) 
4172 
(27.8%) 








1046 / 4434 
(23.6%) 
1529 / 13699 
(11.2%) 







History of stroke- no. 
(%) 
304 (13.1%) 457 (12.4%) 296 (12.8%) 460 (12.2%) 
501/ 4434 
(11.3%) 
1624 / 13699 
(11.9 %) 
2889 / 5205 
(55.5%) 









Abbreviations: AF: atrial fibrillation; CAD: coronary artery disease; CrCl: creatinine clearance; DOAC: direct oral anticoagulant; SD – standard deviation   
 
Table 4 : Baseline characteristics of patients in the  DIRECT registry.  
 
DIRECT registry 
Baseline characteristics of patients treated by DOAC only 
DOAC Dabigatran Apixaban Rivaroxaban Edoxaban 





Age : mean ± SD 70.7 ± 11.2 
Female-no (%) 656/1739 (37.7%) 
Male - no. (%) 1083/1739(62.2%) 
HAS-BLED score 2.2 ± 1.1 
CHA2DS2-VASc score 3.0 ± 1.8 
CrCl  (ml/min) 70.7 ± 31.4 
       Baseline characteristics of patients treated by DOAC + single antiplatelet / dual antiplatelet 






Age - mean ± SD 71.3±8.8 76.6±8.6 73.0±7.2 78.1±8.4 






Male — no. (%) 93 (76.8%) 96 (59.6%) 88 (80.7%) 50 (58.1%) 
HAS-BLED score 3.5±1.0 3.9±0.9 3.9±1.0 4.1±1.0 
CHA2DS2-VASc score 3.9±1.5 5.0±1.6 4.6±1.5 5.1±1.6 
CrCl (ml/min) 69.2±22.0 53.5±19.8 66.1±23.0 53.3±21.7 
AF – no. (%) 121/477 (25.4%) 161/477 (33.8%) 109/477 (22.9%) 86/477 (18.0%) 












Study name Outcome Time point Statistics for each study MH odds ratio and 95% CI
MH odds Lower Upper Relative Relative 
ratio limit limit Z-Value p-Value weight weight
AUGUSTUS ISTH major bleeding 6 months 2,131 1,287 3,527 2,942 0,003 50,96
PIONEER AF PCI ISTH major bleeding 12 months 0,910 0,523 1,583 -0,335 0,738 49,04
1,404 0,609 3,233 0,796 0,426
0,01 0,1 1 10 100







Studies assessing patients with AF and ACS/PCI 
Safety outcome 
From the forest plot, we can see that the use of  triple therapy of apixaban, P2Y12 and aspirin 
doubles the risk of bleeding  compared to the dual therapy of apixaban and P2Y12 inhibitor,           
(M-H OR: 2.131, 95% CI: 1.287 – 3.527, p= 0.003; ➤ Figure 2 and Table 5). The summary 
effect shows a 40% increase in the risk of bleeding with the use of triple therapy regimen 
though this is found to be statistically non-significant (M-H OR: 1.404, 95% CI 0.609 – 
3.233, p=0.426). Publication bias cannot be assessed with just two included studies. 
 
 









MH Odds ratio (95% CI) 
(Random effects model) 
 
No of events / Total no (%) 
AUGUSTUS 48/1145 23/1143 2.131 (1.287 – 3.527) 
PIONEER AF PCI 25/706 27/696 0.910 (0.523 – 1.583) 
Overall 
1.404 (0.609 – 3.233) 







It is also interesting to mention that when the different dose regimens from a subanalysis of 
the REDUAL PCI with two different P2Y12 inhibitors (ticagrelor and clopidogrel) were 
compared, the higher dose of dabigatran (dabigatran etexilate 150 mg) plus clopidogrel 
increased the risk of bleeding by 65% (M-H OR: 1.654, 95% CI 0.746 – 3.667, p=0.216) 
compared to use of a lower dose of dabigatran (dabigatran etexilate 110 mg) whereas 
ticagrelor plus dabigatran etexilate 150 mg decreased the risk of bleeding by around 15% (M-
H OR: 0.843, 95% CI 0.138 – 5.141, p=0.853) over its lower dose counterpart [➤ Figure 3 
and Table 6]. None of the treatment effects were of statistical significance.  
The confidence intervals (CIs) were wider in the ticagrelor arm as there was a relatively small 
subgroup of patients receiving it compared to clopidogrel. The residual weight of a treatment 
effect is directly proportional to the surface area of the point estimate. This is represented in 
the forest plot by the area of the point estimates of the respective regimens. The higher the 
weight assigned, the larger will be the point estimate. 








Intervention Comparator MH Odds ratio 
(95%CI) 
Random effects model 
 
No of events / Total no (%) 
REDUAL PCI (ticagrelor) 2/104 3/132 0.843 (0.138 – 5.141) 
REDUAL PCI (clopidogrel) 14/659 11/849 1.654 (0.746 – 3.667) 
Overall 
1.482 (0.715 – 3.072) 
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Study name Outcome Time point Statistics for each study MH odds ratio and 95% CI
MH odds Lower Upper Relative Relative 
ratio limit limit Z-Value p-Value weight weight
AUGUSTUS MACE 6 months 0,985 0,702 1,382 -0,086 0,931 64,92
PIONEER AF PCI MACE 12 months 0,858 0,542 1,360 -0,650 0,516 35,08
0,939 0,715 1,233 -0,455 0,649
0,01 0,1 1 10 100







➤ Figure 4 and 5 provide the forest plots for the efficacy endpoints of the composite 
endpoint of thromboembolic events (MACE) and death. ➤ Tables 7 and 8 provide the data 
for the MACE and death efficacy endpoints respectively. For the AUGUSTUS trial, the 
composite endpoint of MACE considered here refers to all cause death or ischemic events. 
For the PIONEER AF PCI, it was defined as the composite of death from cardiovascular 
causes, myocardial infarction, or stroke. So, ‘death from cardiovascular causes’ was the 
estimate for the endpoint of death.   
On analysing the efficacy endpoints of both MACE and death of the included studies 
separately, there was a small non-significant reduction with the use of triple therapy over dual 
therapy (MACE – M-H OR: 0.939, 95% CI 0.715 – 1.233, p= 0.649; death - M-H OR: 0.958, 
95% CI 0.651 – 1.410, p= 0.828). Publication bias cannot be assessed with just two included 
studies. 
Figure 4  –  Forest plot of the included studies for MACE in patients with AF and ACS/PCI  
 
 





MH Odds ratio (95% CI) 
Random effects model 
 
No of events / Total no (%) 
AUGUSTUS 
71/1153 72/1153 0.985 (0.702 – 1.382) 
PIONEER AF PCI 
36/704 41/694 
0.858 (0.542 – 1.360) 
Overall 
0.939 (0.715 – 1.233) 







Study name Outcome Time point Statistics for each study MH odds ratio and 95% CI
MH odds Lower Upper 
ratio limit limit Z-Value p-Value
AUGUSTUS Death 6 months 0,973 0,618 1,533 -0,116 0,908
PIONEER AF PCI Death 12 months 0,918 0,440 1,917 -0,227 0,821
0,958 0,651 1,410 -0,218 0,828
0,01 0,1 1 10 100






Figure 5  –  Forest plot of the included studies for the risk of death in patients with AF and 




Table 8  –  Risk of death in patients with AF and ACS/PCI  
 
 
The same can be said when analysing the composite efficacy endpoint of MACE of the sub 
analysis of the REDUAL PCI which favours the use of the higher dosage of dabigatran 
irrespective of the type of antiplatelet used, but not statistically significant. (OR: 0.689, 95% 
CI: 0.342 – 1.387, p= 0.297) [➤ Figure 6 and Table 9]. The CIs were wider in the arm 
where ticagrelor was administered as there was a relatively small subgroup of patients 




MH Odds ratio (95% CI) 
Random effect model 
 
No of events / Total no (%) 
AUGUSTUS 
38/1153 39/1153 
0.973 (0.618 – 1.533) 
PIONEER AF PCI 
14/704 15/694 
0.918 (0.440 – 1.917) 
Overall 
0.958 (0.651 – 1.410) 

















Odds ratio (95% CI) 
Random effects model 
 
No of events / Total no (%) 
REDUAL PCI (ticagrelor) 2/104 6/132 0.477 (0.055 – 4.114) 
REDUAL PCI (clopidogrel) 16/659 27/849 0.720 (0.343 – 1.508) 
Overall 
1.404 (0.609 – 3.233) 
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From our analysis, we have found that there is a significant increase in major bleeding with 
the use of DOAC plus antiplatelet therapy (60%) instead of DOAC alone across all the 
included studies (M-H OR: 1.598, 95% CI 1.430 – 1.785, p=0.000) compared to using DOAC 
plus antiplatelet therapy (➤ Figure 7 and Table 10). All of the treatment effects of the 
respective regimens had statistical significance. Both the lower doses and the higher doses of 
dabigatran and edoxaban plus antiplatelet therapy produced significant major bleeding. 
Among the two doses of dabigatran, the combination therapies of dabigatran etexilate 110 mg 
with antiplatelet therapy saw an 81% increased risk of bleeding (M-H OR: 1.807, 95% CI 
1.335 – 2.445, p=0.000) and dabigatran etexilate 150 mg with antiplatelet therapy saw a 70% 
increased risk of bleeding (M-H OR: 1.695, 95% CI 1.279 – 2.245, p=0.000) over their 
monotherapy counterparts. In case of edoxaban, the higher dose (60 mg) with antiplatelet 
therapy produced 76% increased risk of bleeding (M-H OR: 1.765, 95% CI 1.274 – 2.445, 
p=0.001) whereas the lower dose (30 mg) with antiplatelet therapy saw a 50% increased risk 
of bleeding with borderline significance (M-H OR: 1.500, 95% CI 0.999 – 2.253, p=0.050) 
over just edoxaban 60mg or 30 mg doses respectively. The combination therapy of apixaban 5 
mg and rivaroxaban 20 mg saw an increase of 69% (M-H OR: 1.693, 95% CI 1.341 – 2.138, 
p=0.000) and 36 % increased risk of bleeding (M-H OR:1.366 , 95% CI:1.113 – 1.677, 
p=0.003) when compared to apixaban and rivaroxaban monotherapies. 
The residual weights assigned to ROCKET AF and ARISTOTLE trials are higher than those 
assigned to the RE-LY and the ENGAGE AF TIMI 48 trials. This is represented in the forest 
plot by the area of the point estimates of the respective regimens. The higher the weight 
assigned, the larger will be the point estimate.   
The robustness of the analysis was confirmed on performing a one way sensitivity analysis. It 
shows that similar results are obtained regardless of which study is excluded (➤ Figure S1). 
On visual inspection, an asymmetry of the funnel plot was observed (➤ Figure S1p). 
However, the Egger’s regression test did not reveal any publication bias                                  















DOAC + APT 
DOAC MH Odds ratio (95% CI) 
Random effect model 
 
No of events / Total no (%) 
ENGAGE AF TIMI48 (E 30) 35/1625 73/5046 1.500  (0.999 – 2.253) 
ENGAGE AF TIMI48 (E 60) 59/1642 102/4953 1.765  (1.274 – 2.445) 
ARISTOTLE 114/2233 211/6852 1.693  (1.341 – 2.138) 
RE-LY (DE110) 91/2322 82/3693 1.807  (1.335 – 2.445) 
RE-LY (DE150) 102/2304 100/3772 1.695  (1.279 – 2.245) 
ROCKET AF 171/2586 224/4545 1.366  (1.113 – 1.677) 
Overall 
1.598  (1.430 – 1.785) 
p = 0.000 
 
















For computing the composite efficacy endpoint of MACE, we combined the individual 
efficacy endpoints. It should be noted that only the odds ratio is used here for the outcomes of 
MACE in the random effects model. This is due to the fact that the means of the individual 
outcomes cannot be used to compute the Mantel Haenszel Odds ratio.  
The summary effect shows a 36% statistically significant increase in the risk of ischemic 
events (OR 1.362, 95% CI 1.174 – 1.580, p = 0.000) with the use of a DOAC with antiplatelet 
therapy rather than DOAC alone (➤ Figure 8 and Table 11). From the RE-LY trial, out of 
the two doses of dabigatran, we see that there is a 64% increase in the risk of ischemic events 
with the use of the combination of dabigatran etexilate 150mg with antiplatelet therapy (OR 
1.640, 95% CI 1.086 – 2.478, p = 0.019) and a 43% increased risk of borderline significance 
with dabigatran etexilate 110mg (OR: 1.437, 95% CI 0.981 – 2.104, p = 0.063). From the 
ENGAGE AF TIMI48, there is a 25% increase in the MACE events (OR: 1.255, 95% CI 
0.870 – 1.810, p= 0.225) on using 60 mg edoxaban and a 14% increase with the use of 30 mg 
edoxaban (OR: 1.139 95% CI: 0.712 – 1.821, p= 0.587). From the ARISTOTLE trial, there is 
a 37 % risk increase with the use of apixaban with antiplatelet therapy over the sole use of 
apixaban (OR: 1.368, 95% CI 0.947 – 1.975, p= 0.095). And the ROCKET AF, there was a 
35 % increase with the use of rivaroxaban with antiplatelet therapy over using rivaroxaban 
alone (OR: 1.355, 95% CI:1.028 – 1.784, p= 0.031) 
The residual weight assigned to ROCKET AF is higher relative to the other trials. This is 
represented in the forest plot by the area of the point estimates of the respective regimens. The 
higher the weight assigned, the larger will be the point estimate. 
The robustness of the analysis was confirmed when a one way sensitivity analysis was 
performed. It shows that similar results are obtained regardless of which study is excluded 
(➤Figure S2). 
On visual inspection, an asymmetry of the funnel plot was observed (➤Figure S2p). And the 
Egger’s regression test did not reveal any publication bias (y - intercept: -0.246, 95% CI: -











DOAC + APT DOAC Odds ratio (95% CI) 
Random effect model 
 
No of events / Total no (%) 
RE-LY (DE110) 53/2343 59/3672 1.437 (0.981 – 2.104) 
RE-LY (DE150) 49/2318 52/3758 1.640 (1.086 – 2.478) 
ENGAGE AF TIMI48 (E 30) 30 / 1625 82 / 5046 1.139 (0.712 – 1.821) 
ENGAGE AF TIMI48 (E 60) 67 / 1642 146 / 4953 1.255 (0.870 – 1.810) 
ARISTOTLE 48 / 2233 120 / 6852 1.368 (0.947 – 1.975) 
ROCKET AF 110 / 2586 148 / 4545 1.355 (1.028 – 1.784) 
Overall 
1.362 (1.174 – 1.580) 
 
p = 0.000 
 
 












The summary effect shows a 22 % borderline significance increase in the risk of stroke or SE 
(M-H OR 1.222, 95% CI 0.978 – 1.527, p = 0.077) with the use of a DOAC with antiplatelet 
therapy rather than DOAC alone (➤Figure 9 and Table 12). From the RE-LY trial, out of 
the two doses of dabigatran, we see that there is a 2-fold increase in the risk of stroke or SE 
with the use of the combination of dabigatran etexilate 150mg with antiplatelet therapy (M-H 
OR 1.357, 95% CI 1.357 – 3.573, p = 0.001) and a 52% increased risk of statistical 
significance with dabigatran etexilate 110mg (M-H OR: 1.522, 95% CI 1.010 – 2.293, p = 
0.045). From the ENGAGE AF TIMI48, there is a 9% increase in the risk of stroke or SE (M-
H OR: 1.092, 95% CI 0.725 – 1.644, p= 0.675) on using 30 mg edoxaban but a slight 
decrease in the risk with the use of 60 mg edoxaban (M-H OR: 0.922, 95% CI: 0.567 – 1.498, 
p= 0.742). From the ARISTOTLE trial, there is almost no difference with the use of apixaban 
with antiplatelet therapy or just apixaban (M-H OR: 0.990, 95% CI 0.694 – 1.413, p= 0.958). 
In the ROCKET AF, there was a 13 % increase in the risk of stroke or SE with the use of 
rivaroxaban with antiplatelet therapy over using rivaroxaban alone (M-H OR: 1.131, 95% CI: 
0.881 – 1.451, p= 0.336). 
The residual weight assigned to ROCKET AF is higher relative to the other trials. This is 
represented in the forest plot by the area of the point estimates of the respective regimens. The 
higher the weight assigned, the larger will be the point estimate. 
On performing the one way sensitivity analysis, a trend of a reduction in the risk of stroke or 
SE was maintained with the use of DOACs alone but they were no longer statistically 
significant for all of the treatment effects (➤Figure S3). 
On visual inspection, no asymmetry of the funnel plot was observed (➤Figure S3p). And the 
Egger’s regression test did not reveal any publication bias (y - intercept: 1.840, 95% CI: -












DOAC + APT DOAC MH Odds ratio (95% CI) 
Random effect model 
 
No of events / Total no (%) 
RE-LY (DE110) 45 / 2322 48 / 3693 1.522 (1.010 – 2.293) 
RE-LY (DE150) 39 / 2304 29 / 3772 2.202 (1.357 -3.573) 
ENGAGE AF TIMI48 (E 30) 32 / 1625 90 / 5046 1.092 (0.725 – 1.644) 
ENGAGE AF TIMI48 (E 60) 22 / 1642 70 / 4953 0.922 (0.567 – 1.498) 
ARISTOTLE 41 / 2233 127 / 6852 0.990 (0.694 – 1.413) 
ROCKET AF 105 / 2586 164 / 4545 1.131 (0.881 – 1.451) 
Overall 1.222 (0.978 – 1.527) 
p = 0.077 
 
Table 12 –  Risk of Stroke / Systemic embolism in the included studies  
 












The summary effect shows a 57 % statistically significance increase in the risk of MI (M-H 
OR 1.569, 95% CI 1.361 – 1.809, p = 0.000) with the use of a DOAC with antiplatelet 
therapy rather than DOAC alone (➤Figure 10 and Table 13). From the RE-LY trial, out of 
the two doses of dabigatran, we see that there is a 57% increase in the risk of MI with the use 
of the combination of dabigatran etexilate 150mg with antiplatelet therapy (M-H OR 1.568, 
95% CI 1.050 – 2.343, p = 0.028) and a 41% increased risk with dabigatran etexilate 110mg 
(M-H OR: 1.410, 95% CI 0.945 – 2.102, p = 0.092). From the ENGAGE AF TIMI48, there is 
a 53% statistically significant increased risk of MI (M-H OR: 1.533, 95% CI 1.232 – 1.906, 
p= 0.000) on using 60 mg edoxaban and a 17% increase in the risk with the use of 30 mg 
edoxaban (M-H OR: 1.173, 95% CI: 0.639 – 2.152, p= 0.607). From the ARISTOTLE trial, 
there is almost a doubling of risk of MI with the use of combination therapy of apixaban with 
antiplatelet over apixaban monotherapy which is statistically significant (M-H OR: 2.219, 
95% CI 1.416 – 3.480, p= 0.001). And finally in the ROCKET AF, there was a 62 % 
statistically significant increased risk of MI with the use of rivaroxaban with antiplatelet 
therapy over using rivaroxaban alone (M-H OR: 1.617, 95% CI: 1.142 – 2.290, p= 0.007). 
Here, the residual weight assigned to the edoxaban 60 mg regimen (42.52%) of the ENGAGE 
trial is higher relative to the other trials whereas it is just 5.49% to the edoxaban 30 mg 
regimen. This is represented in the forest plot by the area of the point estimates of the 
respective regimens. The higher the weight assigned, the larger will be the point estimate. 
The robustness of the analysis was confirmed when a one way sensitivity analysis was 
performed. It shows that similar results are obtained regardless of which study is excluded, 
even with the removal of the RE-LY trial (➤Figure S4a& S4b). 
On visual inspection, no asymmetry of the funnel plot was observed (➤Figure S4p). The 
Egger’s regression test did not reveal any publication bias (y - intercept: -0.00395,                  
95% CI: -3.34614, 3.33824, p= 0.99754). When the RE-LY trial was excluded (for both 
dabigatran etexilate 110 mg and dabigatran etexilate 150mg), the egger’s test did not show 












DOAC + APT DOAC MH Odds ratio (95% CI) 
Random effect model 
 
No of events / Total no (%) 
RE-LY (DE110) 
47 / 2386 51/ 3629 1.410 (0.945 – 2.102) 
RE-LY (DE150) 
48 / 2347 49 / 3729 1.568 (1.050 – 2.343) 
ENGAGE AF TIMI48 (E 30) 
14 / 1625 38 / 5046 1.173 (0.639 – 2.152) 
ENGAGE AF TIMI48 (E 60) 
130 / 1642 263 / 4953 1.533 (1.232 – 1.906) 
ARISTOTLE 
33 / 2233 46 / 6852 2.219 (1.416 – 3.480) 
ROCKET AF 
62 / 2586 68 / 4545 1.617 (1.142 – 2.290) 
Overall 
1.569 (1.361 – 1.809) 
p = 0.000 
 
Table 13 –  Risk of Myocardial Infarction in the included studies  
 
  
Study name Outcome Statistics for each study MH odds ratio and 95% CI
MH odds Lower Upper 
ratio limit limit Z-Value p-Value
RE-LY (DE110) Myocardial Infarction 1.410 0.945 2.102 1.684 0.092
RE-LY (DE150) Myocardial Infarction 1.568 1.050 2.343 2.196 0.028
ENGAGE AF-TIMI48  (Edo 30)Myocardial Infarction 1.173 0.639 2.152 0.514 0.607
ENGAGE AF-TIMI48 (Edo 60)Myocardial Infarction 1.533 1.232 1.906 3.836 0.000
ARISTOTLE Myocardial Infarction 2.219 1.416 3.480 3.475 0.001
ROCKET AF Myocardial Infarction 1.617 1.142 2.290 2.711 0.007
1.569 1.361 1.809 6.208 0.000
0.01 0.1 1 10 100




















The summary effect shows a 29 % statistical significance increase in the risk of vascular death 
(M-H OR 1.293, 95% CI 1.148 – 1.457, p = 0.000) with the use of a DOAC with antiplatelet 
therapy rather than DOAC alone (➤Figure 11 and Table 12). From the RE-LY trial, out of 
the two doses of dabigatran, we see that there is a 28% increase in the risk of vascular death 
with the use of the combination of dabigatran etexilate 150mg with antiplatelet therapy (M-H 
OR 1.278, 95% CI 0.910 – 1.795, p = 0.157) and a 38% increased risk of borderline 
significance with dabigatran etexilate 110mg (M-H OR: 1.382, 95% CI 0.995 – 1.921, p = 
0.054). From the ENGAGE AF TIMI48, there is a 40% increase in the risk of vascular death 
of borderline significance (M-H OR: 1.399, 95% CI 0.990 – 1.976, p= 0.057) on using 60 mg 
edoxaban and a 15% increase in the risk with the use of 30 mg edoxaban (M-H OR: 1.154, 
95% CI: 0.812 – 1.640, p= 0.425). Since in the ARISTOTLE trial, all cause death was  the 
endpoint reported, there is a 16% increase in this risk with the use of apixaban with 
antiplatelet therapy over just apixaban (M-H OR: 1.164, 95% CI 0.882 – 1.536, p= 0.283). In 
the ROCKET AF, there was a 36 % statistically significant increase in the risk of vascular 
death with the use of rivaroxaban with antiplatelet therapy over using rivaroxaban alone (M-H 
OR: 1.359, 95% CI: 1.101 – 1.677, p= 0.004). 
The residual weight assigned to ROCKET AF is higher relative to the other trials, followed by 
the ARISTOTLE trial. This is represented in the forest plot by the area of the point estimates 
of the respective regimens. The higher the weight assigned, the larger will be the point 
estimate. 
The robustness of the analysis was confirmed when a one way sensitivity analysis was 
performed. It shows that similar results are obtained regardless of which study is excluded 
(➤Figure S5). 
On visual inspection, no asymmetry of the funnel plot was observed (➤Figure S5p). But the 
Egger’s regression test did not any reveal publication bias (y - intercept: -0.612,                 













Figure 11   –  Forest plot of the included studies for the risk of vascular death  




DOAC + APT DOAC MH Odds ratio (95% CI) 
Random effect model 
 
No of events / Total no (%) 
RE-LY (DE110) 68/2322 79 / 3693 1.382 (0.995 – 1.921) 
RE-LY (DE150) 61 / 2304 78 / 3772 1.278 (0.910 – 1.795) 
ENGAGE AF TIMI48 (E 30) 44 / 1625 118 / 5046 1.154 (0.812 – 1.640) 
ENGAGE AF TIMI48 (E 60) 48 / 1642 105 / 4953 1.399 (0.990 – 1.976) 
ARISTOTLE 71 / 2233 188 / 6852 1.164 (0.882 – 1.536) 
ROCKET AF 162 / 2586 213 / 4545 1.359 (1.101 – 1.677) 
Overall 
1.293 (1.148 – 1.457) 
p = 0.000 
 















The 2018 European Society of Cardiology (ESC) consensus document on the management of 
antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCIs [63], an 
update of the 2014 ESC consensus document on the same topic [64] and had put forth a series 
of consensus statements recommending the use of  DOAC as part of triple or dual therapy are 
safer than VKA therapies like warfarin and  that  dual therapy with an oral anticoagulant plus 
one P2Y12 inhibitor (preferably clopidogrel) to be considered in patients who have a low 
thrombotic risk but have a high bleeding risk. Both the 2018 document, along with the 2016  
ESC Guidelines for the management of atrial fibrillation mention that AF patients with a 
stable vascular disease in the previous 12 months  should be managed by oral anticoagulation 
alone. The results from our meta-analysis further provide scientific evidence in support of the 
above-stated agreements.  
AF patients with ACS / PCI 
 The results from our analysis are in line with the findings of similar meta-analyses performed 
in the context of AF patients with ACS or undergoing PCI [66, 67][77]. The publication of the 
results of the ENTRUST AF-PCI completes the quartet of DOACs (dabigatran etexilate, 
rivaroxaban, apixaban and edoxaban) in this backdrop, although the data from the 
aforementioned trial could not be explored in the meta-analysis owing to its design. Also, we 
must acknowledge the fact that there are significant differences between the trials in terms of 
the inclusion criteria, the number of patients enrolled and the dosages administered. Out of the 
4 randomised controlled trials, we evaluated the safety and efficacy outcomes of the triple 
therapy and dual therapy of the PIONEER AF PCI and the AUGUSTUS trials.  For the 
REDUAL PCI, we investigated the two doses of dabigatran with the P2Y12 inhibitors used. It 
should be noted that though both REDUAL PCI and PIONEER AF PCI had open-label 
designs, the blinding of the outcome adjudicators were appropriate. The same is applicable to 
the ENTRUST AF-PCI trial.  
Major bleeding 
Analysing the forest plot of the primary safety endpoint of ISTH major bleeding, we can 
observe that the point estimate is skewed in favour of dual therapy of DOACs. This is in large 
part attributed to the treatment effects of the apixaban regimen. There is a doubling of the risk 
of bleeding in the triple therapy arm of apixaban compared to its dual therapy counterpart (M-
H OR: 2.131, 95% CI: 1.287 – 3.527, p= 0.003). Although the treatment effect of the 
rivaroxaban regimen shows an inclination towards triple therapy (M-H OR: 0.910, 95% 
CI:0.523 – 1.583, p = 0.426), the relative weights assigned by the random effects model 
shows that the AUGUSTUS trial holds more weight over the PIONEER AF PCI trial. As 
mentioned before, the reason for this boils down to the dosages administered, patients 
enrolled and the trial design. Firstly, in PIONEER AF PCI, the lower doses of rivaroxaban 
(2.5 mg b.i.d, later to 15 mg) was provided in the triple therapy arm, but not the approved 
dosage of rivaroxaban (20 mg) for AF patients as was the case in ROCKET AF trial. This 
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decision was taken into consideration based on the results of the ATLAS ACS–TIMI 46 trial 
where ACS patients given 15 -20 mg of rivaroxaban along with dual antiplatelet therapy 
experienced an increased risk in bleeding [68]. Secondly, patients were not randomised to 
dual antiplatelet therapy but based on the clinicians’ discretion which could have introduced 
bias. The low Jadad score of 2 is representative of the quality of this study. Unlike the 
PIONEER trial, the AUGUSTUS trial provided the recommended dose of apixaban for 
treating AF to the enrolled patients. The randomisation of patients was appropriate in terms of 
blinding of the patients. The two-by-two factorial design of the trial allowed stratifying the 
patients in both arms on either to aspirin or its equivalent placebo. 
From the forest plot for the efficacy endpoints of MACE and death, we can see that the signal, 
though slightly non-significant, is in favour of triple therapy of both the factor Xa inhibitors 
as aspirin still plays a considerable role in preventing stent thrombosis. Around 65 -66% of 
the patients received a drug eluting stent (DES) and 31 – 32% received a bare metal stent 
(BMS) in the dabigatran arms of the PIONEER AF PCI trial. In the AUGUSTUS trial, out of 
a total of 2297 patients in both apixaban and VKA regimens, about 877 (38.2%) underwent 
elective PCI though there is no mention of the type of stent. As far as the secondary efficacy 
endpoints of thrombotic events are concerned, both the trials were underpowered to detect 
small relevant ischemic events. Moreover, due to the heterogeneity in the reporting of the 
individual efficacy endpoints between the trials, the interpretation of the results is varied.    
REDUAL-PCI trial 
In the RE-DUAL trial, as only the dual therapy of both the doses of dabigatan were compared 
with the triple therapy of VKA, we could not analyse the doses of dabigatran with that of 
rivaroxaban and apixaban due to the differences in the dosing regimens. However, a bivariate 
analysis of the PIONEER AF-PCI and RE-DUAL PCI trial has revealed that all combinations 
of rivaroxaban (rivaroxaban 15 mg o.d. and 2.5 mg b.i.d) and dabigatran (dabigatran etexilate 
110 mg and dabigatran etexilate 150 mg) had a better net clinical benefit (NCB) when 
compared to the VKA regimen [69].  
Looking at the type of antiplatelet users in the RE-DUAL trial, there were 659 (86.4%) 
clopidogrel users and 104 (13.9%) ticagrelor users in the dabigatran etexilate 150 arm and 849 
(86.5%) clopidogrel users and 132 (13.5%) ticagrelor users in the dabigatran etexilate 110 
arm. Since ticagrelor, a p-gp inhibitor was made available for a minority of AF patients as an 
adjunct therapy, like those with a higher risk for thromboembolic and bleeding events, it is 
interesting to see that the higher dose of dabigatran with ticagrelor was found to reduce the 
risk of major bleeding as defined by TIMI compared to the lower dose of dabigatran with 
ticagrelor. However, the overall effect of major bleeding was increased by 48% with the use 
of the higher dose of dabigatran with the corresponding antiplatelets (M-H OR: 1.482, 95% 
CI 0.715 – 3.072, p=0.290) compared to its lower dose. When it comes to the MACE 
composite efficacy endpoint, our analysis revealed that it was in favour of dabigatran etexilate 
150 mg with either clopidogrel or ticagrelor which reduced the risk of thromboembolic events 
[OR  0.689, 95% CI 0.342 – 1.387, p= 0.297]. And in the main study as well, it was shown 
that the rates of MI and stent thrombosis were non-significantly higher among the patients 
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who were randomly assigned to receive dabigatran etexilate 110 mg. Notwithstanding, the 
subanalysis of the REDUAL PCI trial involved the non-randomized comparisons of P2Y12 
inhibitors with a wide difference in the number of patients receiving them, therefore the 
elucidation of these results are limited in scope. 
ENTRUST AF PCI trial 
Like the previous 3 trials, the ENTRUST AF PCI trial demonstrated that the dual therapy of 
the approved dosage of the DOAC edoxaban was non inferior to the triple therapy of warfarin 
at least in terms of bleeding, although during the starting 2 week period, the patients in the 
VKA group did not achieve good-quality anticoagulation (INR < 2). 696 out of 751 patients 
(93%) were treated with clopidogrel in the edoxaban arm (60 mg) where 147 (20%) allotted to 
the edoxaban regimen were given the adjusted dose of 30 mg, based on renal impairment 
(moderate or severe), bodyweight ( < 60 kg), or the use of specific strong P-glycoprotein 
inhibitors . Though the efficacy outcomes were similar between the two arms, the 
investigators noted that, as observed with the former trials, there was an increase in MACE 
events in patients who did not take aspirin (namely the dual therapy regimen). This 
phenomenon could be ascribed to the variability of clopidogrel response  and residual platelet 
reactivity in patients due to the CYP2C19 loss-of-function alleles found in such patients 
especially in those with ACS on antiplatelet therapy which have an independent role in 
determining MACE events [70][71].  
Viewpoint 
When we analyse the results of our meta-analysis for these patients, we see that there is an 
overall increased risk of major bleeding observed with triple therapy but a decrease in the 
composite efficacy endpoints of MACE, though it is found to be statistically non-significant. 
Another subanalysis of the REDUAL PCI trial revealed how age influences bleeding rates. 
Japanese patients on dabigatran etexilate 110-mg dual therapy experienced higher bleeding 
rates (26%) compared to the overall cohort of the trial (15.4%) as the elderly in the Japanese 
subpopulation was around 72 %, whereas it was only 22.9%  in the overall dabigatran 
etexilate 110-mg dual therapy group [72]. Also according to  the patients’ clinical 
presentation like ACS in the trials, it was found that there was no association noticed between 
the treatment effect and outcome which leads us to believe that the clinical benefit of DOACs 
may be safeguarded in patients with CAD [73]. In view of the fact that the four trials were not 
adequately powered to assess the ischemic outcomes, the use of triple therapy should be 
limited to those only with high thromboembolic risk and low bleeding risk.  
Many meta-analyses which were performed in the setting of AF patients with ACS/PCI have 
concluded that dual therapy takes precedence over triple therapy. However, it should be noted 
that almost all of these publications have actively made assessments of dual and triple therapy 
where at least one of the comparators had warfarin as the oral anticoagulant of choice [74-77]. 
It is worthy to mention that there were a minority of patients in the ROCKET AF (1.1%) and 
the Aristotle trial (1.7%) who underwent PCI during the study period.  Unfortunately, they 
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were not part of our analysis based on the sample size and since warfarin was the only other 
comparator used in these trials [79, 80]. 
 
DOAC with or without concomitant antiplatelets in AF  
We had included 4 studies based on the randomised controlled trials on AF patients where a 
subanalysis was performed, namely the RE-LY trial, the ROCKET AF trial, the ARISTOTLE 
trial and the ENGAGE AF TIMI48 trial where patients were randomised to dabigatran, 
rivaroxaban, apixaban and edoxaban respectively. In all the 4 trials, aspirin was the 
concomitant antiplatelet of choice in such patients (except in the RE-LY and ENGAGE AF 
TIMI48 trials where clopidogrel was used as well). ROCKET AF had a large number of 
patients with a high CHADS2 score. In our analysis, we found that there is a significant 
increase in both major bleeding without any benefit in reducing thromboembolic events with 
the adjunct use of antiplatelet therapy along with any DOAC regardless of the dosage. 
Statistical significance was observed with the safety and efficacy endpoints. Our results 
corroborate with the results obtained by Kumar et al [81] in their meta-analysis, the difference 
being we also reported the efficacy endpoints of stroke or SE, MI AND death. 
Major bleeding 
Among the 4 combination therapies, our analysis revealed that the dabigatran etexilate 110 
mg plus antiplatelet therapy escalated the risk of bleeding by 81%, followed by 70 % increase 
in the same risk by dabigatran etexilate 150 mg over the use of dabigatran doses alone. 
Edoxaban 60 mg and 30 mg with an antiplatelet therapy had a 76% and 50% increased risk of 
bleeding respectively. Both of these trials allowed either aspirin or clopidogrel to be used as a 
single antiplatelet therapy but the majority of them were on concomitant aspirin. Similar high 
rates of bleeding are observed with the other two trials where only aspirin was received by the 
patients with apixaban combination therapy having a 69 % increased risk of bleeding 
followed by rivaroxaban combination therapy having a 37% risk increase in bleeding events. 
As it has been shown that patients with paroxysmal AF are categorised as those with a low 
risk of bleeding [82], the addition of an antiplatelet agent in such patients does not seem to 
have any added benefit but seems to aggravate the risk.  
Thromboembolic events 
One of the main reasons for the addition of antiplatelet therapy to anticoagulant therapy is to 
reduce the risk of thrombotic events in the patients with vascular disease. However, the data 
we obtained shows that when DOAC plus antiplatelet therapy instead of DOAC were used in 
these patients in the included trials, the risk of ischemic complications increased by 36%, risk 
of stroke or SE saw a 22% increase, efficacy endpoint of vascular death saw a 29% increase 
and a 57% increase in MI risk. Among the DOACs combination therapies, dabigatran 
etexilate 150 mg plus antiplatelet therapy seems to have a significant risk of causing MACE 
(64%). The same drug regimen is seen to double the risk of stroke / SE compared to the other 
DOAC combination therapies. And in the case for MI, apixaban plus the use of aspirin 
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doubles the risk in patients followed by rivaroxaban 20 mg combination therapy. It should be 
noted here that though both the add on therapies of dabigatran increases the risk of MI in 
patients, we obtained the data only for concomitant aspirin therapy. Nevertheless, on 
performing a sensitivity analysis by excluding the RE-LY trial, there was no change in the 
results. Previously, from the RE-LY trial, there were concerns of the risk of MI with the 
dabigatran doses when compared to warfarin although it was found to be a non-significant 
increase in the risk [83, 84]. Also, a recently conducted Danish nationwide cohort study from 
their validated healthcare registries involving AF patients on oral anticoagulation for stroke 
prevention found that there were no significant risk differences among DOACs in their effects 
on MI or all-cause mortality and that dabigatran to be superior in terms of this outcome 
against both apixaban and rivaroxaban [85, 86]. For the efficacy endpoint of vascular death, 
our results show edoxaban 60 mg causes a 40% increase in this risk followed by an almost 
equivalent 38% increase using dabigatran etexilate 110 mg and by rivaroxaban. It should be 
noted that the ROCKET AF recruited patients with the highest CHADS2 score. 
Why the increase in the bleeding and thromboembolic events? Viewpoint 
 Several reasons can be provided for these occurrences. Firstly, we have to consider the 
baseline characteristics of the recruited in these trials. A lesser proportion of patients had 
arterial vascular diseases like CAD and stroke (< 38%). The addition of the antiplatelet 
therapy was not randomised in these trials leading to selection bias where patients with less 
risk of developing the complications would have been selected for the concomitant therapy, 
mainly aspirin, with the use of clopidogrel or dual antiplatelet therapy being rare and 
prasugrel or ticagrelor not provided. Moreover, these subgroup analyses were performed 
sometime during the trial and not until the completion of the trials. Data published in these 
trials were those of the annualised events rates. Again, these could have exaggerated the 
results as well. Also, patients’ adherence to the study drugs is questionable. In the ROCKET 
AF trial, temporary interruption in taking the oral anticoagulants led to an increase in the 
stroke and bleeding risks [87]. In the RE-LY trial, it is believed that the dabigatan etexilate 
capsules composed of drug-coated tartaric acid which assists in creating an acidic 
microenvironment for gastrointestinal absorption of the drug was responsible for almost 12% 
of dyspepsia, promoting a higher rate of drug discontinuation [32], [53]. A similar higher rate  
of  non-adherence to dabigatran was reported among AF patients [100], though both 
rivaroxaban and dabigatran have better persistence compared to VKA [101]. We will also 
have to consider the prior VKA antagonist exposure of these patients. Another observational 
study using the registry data of Danish cohort of patients showed that among patients with 
VKA naïve patients and VKA experienced patients, warfarin experienced patients who 
switched to dabigatran had an increased rate of MI, during an early treatment analysis [88]. 
Since a stratification of patients with prior VKA use was not performed in our analysis, this 
should be done in a future study. In addition, the use of concomitant, contraindicated 
medications by these patients need to be considered. This could have an impact on the blood 
concentration of the anticoagulants, thereby affecting the bleeding risk [89]. A study reported 
potentially inappropriate dosing of drugs and switching between the anticoagulants in a 
proportion of AF patients aged over 65 years who were unsuitable for warfarin [99]. 
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It should be noted that the reported events for the efficacy endpoint of MI from the RE-LY 
trial could not be obtained from the included study but from a similar meta-analysis which 
focused on the use of concomitant aspirin, but not clopidogrel [90]. 
AFIRE trial 
The AFIRE trial was an open label , multicentre Phase 4 randomised controlled trial 
conducted in Japan where patients were randomised to either rrivaroxaban monotherapy     
(15 mg or 10 mg based on the creatinine clearance value) or rivaroxaban combination therapy 
with a single antiplatelet therapy (either aspirin or a P2Y12 inhibitor), to patients with AF 
who had undergone PCI or CABG performed more than a year before registration or those 
had angiographically confirmed CAD but not requiring revascularization. The trial 
demonstrated  superiority of rivaroxaban monotherapy over the combination therapy in terms 
of bleeding events and non-inferiority in terms of the efficacy endpoints of stroke, SE, MI 
unstable angina requiring revascularization, or death. The trial had appropriate statistical 
power to detect the difference in the two regimens but because of an increased risk of death of 
any cause in the combination therapy and the high withdrawal rate, the trial had to be 
terminated early. Considering these facts, the results of the trial can be overestimated. 
 
Observational study   
DIRECT registry 
The DIRECT registry was a single centre prospective, observational study based in Japan 
which analysed the data of patients with AF on both DOAC and concomitant antiplatelet 
therapy (➤Table 4). All the 4 DOACs were used for the analysis. The results of this study 
did show that patients on concurrent antiplatelet therapy did indeed have an increased 
bleeding risk. The study though had considerable limitations. It was a single centre 
observational study with relatively short follow-up duration. Confounding factors would have 
affected the analyses of the results. Nevertheless, the study does provide some information 
which can help in clinical practice specific to the geographical area.  
There were a few other observational studies as well where a VKA was used as the 
comparator drug.  A single centre observational study conducted in France observed that for 
dual therapy with clopidogrel, dabigatran lead to an increase in MACE events but with similar 
rates of major bleeding compared with VKA in AF patients with ACS/PCI [91]. Here, the 
lower dose (dabigatran etexilate 110 mg) of dabigatran was administered to the treatment 
group while fluindione was the VKA for the control group patients and. It should be noted 





The implications of the results of our meta-analysis are manifold. Firstly, it adds to the 
established body of evidence, for at least the risk of major bleeding, that triple therapy is a 
bane rather than a boon for patients with AF especially those who with a comorbidity of 
coronary disease or those who are undergoing PCI, but has a slight benefit when it comes to 
preventing thromboembolic events in these patients. The type of stenting used to treat these 
patients also matter as it has been found out that the newer generation of drug-eluting stents 
(DES) in preventing stent thrombosis over their equivalent first-generation bare-metal stents 
[92]. Secondly, there is no benefit of an add-on antiplatelet therapy on top of a single 
administration of DOAC alone, regardless of the dosage in AF patients with stable vascular 
disease. Statistically speaking, our results have shown that the use of DOAC alone was 
superior to DOAC plus antiplatelet therapy in preventing both major bleeding and the 
ischemic and thromboembolic endpoints. The authors of the subgroup analysis of the RE-LY 
and ROCKET AF trial have concluded the same. Furthermore, it is in line with the current 
guidelines on high-risk AF patients with stable vascular disease. Our results seem to reinforce 
the notion. 
Out with the old, in with the new?  
A retrospective analysis of the Norway registries have found that at least in the context of AF 
patients with concomitant comorbidities like vascular disease, heart failure, and diabetes were 
associated with warfarin initiation, and previous stroke, age 65-74 and female sex with the 
initiation of DOACs [8]. Moreover, VKAs remain the choice therapy for many diseases (e.g. 
valvular atrial fibrillation and mechanical prosthetic heart valves) [21]. Gene polymorphisms 
of CYP2C9 (specially CYP2C9*2 and CYP2C9*3) have been implicated in the decrease in 
the metabolisation of warfarin and as such, prolonging the anticoagulant activity of warfarin 
[93]. Based on these genetic variants, the dosing should be tailored accordingly. 
Pharmacogenetic testing  
The recent consensus statement on guiding P2Y12 Receptor Inhibitor Treatment in PCI [71] 
recommends the use of platelet function testing (PFT) in patients who had a recent stent 
thrombosis especially considering the high variability of clopidogrel response in such patients 
based on gene polymorphisms. The results of PFT and the presence of certain genetic markers 
will not only assist in anticipating the thrombotic events but bleeding events as well. 
Polymorphisms of CYP2C9 and CYP2C19 deem to have considerable effects on the 
metabolism of both warfarin and clopidogrel respectively. Consequently, genetic testing of 
such patients is warranted. Apart from CYP2C9, studies have also noted that in patients with 
ACS receiving clopidogrel treatment, the platelet reactivity in those carrying the CES1 143E-
allele was lower than that in 143G-homozygotes. CES1 is a hepatic serine hydrolase that is 
also involved in the bioactivation of clopidogrel. The interracial differences of these 
polymorphisms have to be acknowledged as well as it was noted that the prevalence of 
clopidogrel resistance is expected to be higher in Asians compared to Caucasians [45].  
 43 
Strengths and Limitations    
In this meta-analysis, we have directly assessed the bleeding risk in AF patients with 
associated coronary disease and/or PCIs where the primary oral anticoagulants used are 
DOACs. Also, this study has investigated the contrast between using a DOAC with an 
associated antiplatelet/s against a DOAC alone. The veracity of the results of our meta-
analysis is further strengthened by the robustness of the sensitivity analysis. Also, we 
demonstrated that there was no evidence of publication bias through the use of funnel plots 
and egger’s tests.  
But this meta-analysis has its limitations as well. Firstly, the study design, the duration of 
therapies, the follow-ups and the reporting of the outcomes of the trials differed from each 
other. We acknowledge the fact that different bleeding definitions were reported in the 
different studies and as such, limited our ability to analyse the different safety outcomes from 
all the trials. Furthermore, in the setting of AF with ACS/PCI, the apparent heterogeneity in 
the composite efficacy endpoint of MACE defined in the different trials does alter the 
interpretation thereby leading to misleading conclusions [94]. Apart from the AUGUSTUS 
trial, the other three trials didn’t assess the antiplatelet regimens separately. Importantly, since 
we have adopted a random effects model and the number of studies is less, the between 
studies variance is of poor precision, necessitating a Bayesian method [95]. As there was no 
triple therapy arm of the dabigatran doses in the REDUAL PCI and ENTRUST AF PCI, their 
exclusion from the meta-analysis does not provide a clear and complete picture.  
In the setting of AF patients with an indication for concomitant antiplatelet therapy, there was 
no randomisation of antiplatelet therapy performed and only a minority of patients was using 
an antiplatelet agent continuously throughout the studies. The results published were that of a 
post-hoc analysis. They should always be interpreted cautiously as these subgroups will not 
be powered for a formal statistical testing of each individual subgroup. 
Secondly, our meta-analysis, to provide an overall outlook, pooled the available data for the 
outcomes of interest irrespective of the bleeding and stroke risk of these patients. However, it 
should be noted that the included trials in the setting of AF with ACS/PCI was enriched by 
patients who had high HAS-BLED and CHA2DS2-VASc scores (➤Table 2). Due to the 
unavailability of specific datasets, a sub analysis of those aged 65-74 years and those over 75 
years could not be performed. Furthermore, we had access to only study-level data instead of 
patient level data which would help in performing the time to event analysis. It would allow 
exploring and making refinements based on sex specific differences, ethnicities, clinical 
presentations of the patients.  
Thirdly, since a meta-regression could not be performed, the implications of our study results 
when it comes to major bleeding in AF patients with an arterial vascular disease like CAD can 
be difficult to interpret given the fact that the included trials each had fewer patients with this 





Some of the ongoing trials in the setting of AF with ACS/PCI include the Phase 4 Dabigatran 
Versus Warfarin With NVAF Who Undergo PCI (COACH AF PCI) trial [NCT03536611], 
CAPITAL PCI AF [NCT03331484] and the AVIATOR 2 observational study [97]. The status 
of the RT-AF trial remains unknown [98]. 
Conclusion 
In conclusion, our meta-analysis shows that in the setting of AF patients with ACS / PCI, dual 
therapy of a DOAC plus an antiplatelet (P2Y12 inhibitor like clopidogrel) is preferable over a 
triple therapy containing aspirin. In the setting of AF patients with an indication for 
concomitant antiplatelets, it was shown that there was a statistically significant increase in 
both major bleeding and thromboembolic events with the concomitant use of antiplatelet 
agents.  Due to the differences in the population of the recruited patients in terms of their 
comorbidities, the concomitant medications and the treatment regimens administered to them 
and the design of the clinical trials, it is advisable for a more calculated and personalised 



















1. Michniewicz, E., et al., Patients with atrial fibrillation and coronary artery disease - 
Double trouble. Adv Med Sci, 2018. 63(1): p. 30-35. 
 
2. Kirchhof, P., et al., 2016 ESC Guidelines for the management of atrial fibrillation 
developed in collaboration with EACTS. Europace, 2016. 18(11): p. 1609-1678. 
 
3. Markides, V. and R.J. Schilling, Atrial fibrillation: classification, pathophysiology, 
mechanisms and drug treatment. Heart, 2003. 89(8): p. 939-43. 
 
4. Violi, F., D. Pastori, and P. Pignatelli, Mechanisms And Management Of Thrombo-
Embolism In Atrial Fibrillation. J Atr Fibrillation, 2014. 7(3): p. 1112. 
 
5. Ice, D.S., et al., Unanswered questions in patients with concurrent atrial fibrillation 
and acute coronary syndrome. Am J Cardiol, 2014. 113(5): p. 888-96. 
 
6. Lubitz, S.A., et al., Challenges in the classification of atrial fibrillation. Nat Rev 
Cardiol, 2010. 7(8): p. 451-60. 
 
7.  Lin, H.J., et al., Stroke severity in atrial fibrillation. The Framingham Study. Stroke, 
1996. 27(10): p. 1760-4. 
 
8. Kjerpeseth, L.J., et al., Risk factors for stroke and choice of oral anticoagulant in 
atrial fibrillation. Eur J Clin Pharmacol, 2018. 74(12): p. 1653-1662. 
 
9. Lippi, G., F. Sanchis-Gomar, and G. Cervellin, Chest pain, dyspnea and other 
symptoms in patients with type 1 and 2 myocardial infarction. A literature review. Int 
J Cardiol, 2016. 215: p. 20-2. 
 
10. Sanchis-Gomar, F., et al., Epidemiology of coronary heart disease and acute coronary 
syndrome. Ann Transl Med, 2016. 4(13): p. 256. 
 
11. Virmani, R., et al., Pathology of the vulnerable plaque. J Am Coll Cardiol, 2006. 47(8 
Suppl): p. C13-8. 
 
12. Eikelboom, J.W., et al., Adverse impact of bleeding on prognosis in patients with 
acute coronary syndromes. Circulation, 2006. 114(8): p. 774-82. 
 
13. Lau, D.H., et al., New-onset atrial fibrillation and acute coronary syndrome. Expert 
Rev Cardiovasc Ther, 2010. 8(7): p. 941-8. 
 
14. Kralev, S., et al., Incidence and severity of coronary artery disease in patients with 
atrial fibrillation undergoing first-time coronary angiography. PLoS One, 2011. 6(9): 
p. e24964. 
 
15. Reed, G.W. and C.P. Cannon, Triple oral antithrombotic therapy in atrial fibrillation 
and coronary artery stenting. Clin Cardiol, 2013. 36(10): p. 585-94. 
46 
 
16. Rubboli, A., et al., Periprocedural and medium-term antithrombotic strategies in 
patients with an indication for long-term anticoagulation undergoing coronary 
angiography and intervention. Coron Artery Dis, 2007. 18(3): p. 193-9. 
 
17. Rao, S.V., et al., Impact of bleeding severity on clinical outcomes among patients with 
acute coronary syndromes. Am J Cardiol, 2005. 96(9): p. 1200-6. 
 
18. Capodanno, D. and D.J. Angiolillo, Management of antiplatelet and anticoagulant 
therapy in patients with atrial fibrillation in the setting of acute coronary syndromes 
or percutaneous coronary interventions. Circ Cardiovasc Interv, 2014. 7(1): p. 113-24. 
 
19. Mega, J.L., et al., Rivaroxaban in patients with a recent acute coronary syndrome. N 
Engl J Med, 2012. 366(1): p. 9-19. 
 
20.  Montalescot, G., et al., Duration of Dual Antiplatelet Therapy After Coronary 
Stenting: A Review of the Evidence. J Am Coll Cardiol, 2015. 66(7): p. 832-847. 
 
21. Molteni, M. and C. Cimminiello, Warfarin and atrial fibrillation: from ideal to real 
the warfarin affaire. Thromb J, 2014. 12(1): p. 5. 
 
22. Investigators, A.W.G.o.t.A., et al., Clopidogrel plus aspirin versus oral 
anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with 
Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled 
trial. Lancet, 2006. 367(9526): p. 1903-12. 
 
23. Hart, R.G., L.A. Pearce, and M.I. Aguilar, Meta-analysis: Antithrombotic Therapy to 
Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Annals of 
Internal Medicine, 2007. 146(12): p. 857-867. 
 
24. Mant, J., et al., Warfarin versus aspirin for stroke prevention in an elderly community 
population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the 
Aged Study, BAFTA): a randomised controlled trial. Lancet, 2007. 370(9586): p. 493-
503. 
 
25. De Caterina, R., et al., Vitamin K antagonists in heart disease: current status and 
perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--
Task Force on Anticoagulants in Heart Disease. Thromb Haemost, 2013. 110(6): p. 
1087-107. 
 
26. Goto, K., et al., Anticoagulant and antiplatelet therapy in patients with atrial 
fibrillation undergoing percutaneous coronary intervention. Am J Cardiol, 2014. 
114(1): p. 70-8. 
 
27. Rubboli, A., et al., Meta-analysis of trials comparing oral anticoagulation and aspirin 
versus dual antiplatelet therapy after coronary stenting. Clues for the management of 
patients with an indication for long-term anticoagulation undergoing coronary 
stenting. Cardiology, 2005. 104(2): p. 101-6. 
 
 47 
28. Hansen, M.L., et al., Risk of bleeding with single, dual, or triple therapy with 
warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med, 
2010. 170(16): p. 1433-41. 
 
29. Bhatt, D.L., O PIONEERs! The Beginning of the End of Full-Dose Triple Therapy 
with Warfarin? Circulation, 2017. 135(4): p. 334-337. 
 
30. Comin, J. and D.F. Kallmes, Dabigatran (Pradaxa). AJNR Am J Neuroradiol, 2012. 
33(3): p. 426-8. 
 
31. Stangier, J., Clinical pharmacokinetics and pharmacodynamics of the oral direct 
thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet, 2008. 47(5): p. 285-95. 
 
32. Flaker, G., P.P. Dobesh, and Z.A. Stacy, Pharmacology of Oral Anticoagulants. 
Stroke Prevention in Atrial Fibrillation, 2019: p. 11-34. 
 
33. Eriksson, B.I., D.J. Quinlan, and J.I. Weitz, Comparative pharmacodynamics and 
pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. 
Clin Pharmacokinet, 2009. 48(1): p. 1-22. 
 
34. Furie, B. and B.C. Furie, Mechanisms of thrombus formation. N Engl J Med, 2008. 
359(9): p. 938-49. 
 
35. Perzborn, E., et al., Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb 
Vasc Biol, 2010. 30(3): p. 376-81. 
 
36. Wong, P.C. and X. Jiang, Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor 
induced human platelet aggregation in vitro: comparison with direct inhibitors of 
factor VIIa, XIa and thrombin. Thromb Haemost, 2010. 104(2): p. 302-10. 
 
37. Wang, L., et al., In vitro assessment of metabolic drug-drug interaction potential of 
apixaban through cytochrome p450 phenotyping, inhibition, and induction studies. 
Drug Metabolism and Disposition, 2010. 
 
38. Raghavan, N., et al., Apixaban metabolism and pharmacokinetics after oral 
administration to humans. Drug Metabolism and Disposition, 2009. 
 
39. Nagelschmitz, J., et al., Pharmacokinetics and pharmacodynamics of acetylsalicylic 
acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol, 
2014. 6: p. 51-9. 
 
40. Freedman, S.B., B.J. Gersh, and G.Y.H. Lip, Misperceptions of aspirin efficacy and 
safety may perpetuate anticoagulant underutilization in atrial fibrillation, in European 
Heart Journal. 2015. 
 
41. Kazui, M., et al., Identification of the human cytochrome P450 enzymes involved in 
the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically 




42. Eshaghian, S., et al., Role of clopidogrel in managing atherothrombotic 
cardiovascular disease. Ann Intern Med, 2007. 146(6): p. 434-41. 
 
43. Muller, I., et al., Effects of aspirin and clopidogrel versus oral anticoagulation on 
platelet function and on coagulation in patients with nonvalvular atrial fibrillation 
(CLAFIB). Pathophysiol Haemost Thromb, 2002. 32(1): p. 16-24. 
 
44. Investigators, A., et al., Effect of clopidogrel added to aspirin in patients with atrial 
fibrillation. N Engl J Med, 2009. 360(20): p. 2066-78. 
 
45. Jiang, X.L., et al., Clinical pharmacokinetics and pharmacodynamics of clopidogrel. 
Clin Pharmacokinet, 2015. 54(2): p. 147-66. 
 
46. Giorgi, M.A., et al., Beyond efficacy: Pharmacokinetic differences between 
clopidogrel, prasugrel and ticagrelor, in Expert Opinion on Pharmacotherapy. 2011. 
 
47. Wallentin, L., et al., Ticagrelor versus clopidogrel in patients with acute coronary 
syndromes. N Engl J Med, 2009. 361(11): p. 1045-57. 
 
48. Cannon, C.P., et al., Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial 
Fibrillation. N Engl J Med, 2017. 377(16): p. 1513-1524. 
 
49. Oldgren, J., et al., Dabigatran dual therapy with ticagrelor or clopidogrel after 
percutaneous coronary intervention in atrial fibrillation patients with or without acute 
coronary syndrome: A subgroup analysis from the RE-DUAL PCI trial. European 
Heart Journal, 2019. 
 
50. Gibson, C.M., et al., Prevention of Bleeding in Patients with Atrial Fibrillation 
Undergoing PCI. N Engl J Med, 2016. 375(25): p. 2423-2434. 
 
51. Lopes, R.D., et al., Antithrombotic Therapy after Acute Coronary Syndrome or PCI in 
Atrial Fibrillation. N Engl J Med, 2019. 380(16): p. 1509-1524. 
 
52. Vranckx, P., et al., Edoxaban-based versus vitamin K antagonist-based antithrombotic 
regimen after successful coronary stenting in patients with atrial fibrillation 
(ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet, 2019. 
394(10206): p. 1335-1343. 
 
53. Dans, A.L., et al., Concomitant use of antiplatelet therapy with dabigatran or warfarin 
in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. 
Circulation, 2013. 
 
54. Alexander, J.H., et al., Apixaban vs. warfarin with concomitant aspirin in patients 
with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J, 2014. 35(4): 
p. 224-32. 
 
55. Shah, R., et al., Use of concomitant aspirin in patients with atrial fibrillation: 
Findings from the ROCKET AF trial. American Heart Journal, 2016. 
 49 
56. Xu, H., et al., Concomitant use of single antiplatelet therapy with edoxaban or 
warfarin in patients with atrial fibrillation: Analysis from the engage af-timi48 trial. 
Journal of the American Heart Association, 2016. 
 
57. Sotomi, Y., et al., Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral 
Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients 
in the DIRECT Registry). Am J Cardiol, 2019. 123(8): p. 1293-1300. 
 
58. Yasuda, S., et al., Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary 
Disease. N Engl J Med, 2019. 381(12): p. 1103-1113. 
 
59. Connolly, S.J., et al., Dabigatran versus warfarin in patients with atrial fibrillation. N 
Engl J Med, 2009. 361(12): p. 1139-51. 
 
60. Patel, M.R., et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N 
Engl J Med, 2011. 365(10): p. 883-91. 
 
61. Granger, C.B., et al., Apixaban versus warfarin in patients with atrial fibrillation. N 
Engl J Med, 2011. 365(11): p. 981-92. 
 
62. Giugliano, R.P., et al., Edoxaban versus warfarin in patients with atrial fibrillation. N 
Engl J Med, 2013. 369(22): p. 2093-104. 
 
63. Lip, G.Y.H., et al., 2018 Joint European consensus document on the management of 
antithrombotic therapy in atrial fibrillation patients presenting with acute coronary 
syndrome and/or undergoing percutaneous cardiovascular interventions: A joint 
consensus document of the European Heart Rhythm Association (EHRA), European 
Society of Cardiology Working Group on Thrombosis, European Association of 
Percutaneous Cardiovascular Interventions (EAPCI), and European Association of 
Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-
Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society 
(LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace, 
2019. 
 
64. Lip, G.Y., et al., Management of antithrombotic therapy in atrial fibrillation patients 
presenting with acute coronary syndrome and/or undergoing percutaneous coronary 
or valve interventions: a joint consensus document of the European Society of 
Cardiology Working Group on Thrombosis, European Heart Rhythm Association 
(EHRA), European Association of Percutaneous Cardiovascular Interventions 
(EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the 
Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur 
Heart J, 2014. 35(45): p. 3155-79. 
 
65. Wiviott, S.D., E.M. Antman, and E. Braunwald, Prasugrel. Circulation, 2010. 122(4): 
p. 394-403 
 
66. Lopes, R.D., et al., Safety and Efficacy of Antithrombotic Strategies in Patients With 
Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network 
Meta-analysis of Randomized Controlled Trials. JAMA Cardiol, 2019. 
50 
 
67. Supplementary appendix - Vranckx, P., et al., Edoxaban-based versus vitamin K 
antagonist-based antithrombotic regimen after successful coronary stenting in 
patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 
3b trial. Lancet, 2019. 394(10206): p. 1335-1343. 
 
68. Mega, J.L., et al., Rivaroxaban versus placebo in patients with acute coronary 
syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet, 
2009. 374(9683): p. 29-38. 
 
69. Chi, G., et al., Safety and efficacy of non-vitamin K oral anticoagulant for atrial 
fibrillation patients after percutaneous coronary intervention: A bivariate analysis of 
the PIONEER AF-PCI and RE-DUAL PCI trial. Am Heart J, 2018. 203: p. 17-24. 
 
70. Giusti, B. and R. Abbate, Response to antiplatelet treatment: from genes to outcome. 
Lancet, 2010. 376(9749): p. 1278-81. 
 
71. Sibbing, D., et al., Updated Expert Consensus Statement on Platelet Function and 
Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous 
Coronary Intervention, in JACC: Cardiovascular Interventions. 2019. 
 
72. Ako, J., et al., Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous 
Coronary Intervention in Atrial Fibrillation- Japanese and East-Asian Subgroup 
Analysis of the RE-DUAL PCI Trial. Circ J, 2019. 83(2): p. 327-333. 
 
73. Capodanno, D., Triple antithrombotic therapy after ACS and PCI in patients on 
chronic oral anticoagulation: update. Heart, 2018. 104(23): p. 1976-1983. 
 
74. Golwala, H.B., et al., Safety and efficacy of dual vs. triple antithrombotic therapy in 
patients with atrial fibrillation following percutaneous coronary intervention: a 
systematic review and meta-analysis of randomized clinical trials. Eur Heart J, 2018. 
39(19): p. 1726-1735a. 
 
75. Siddiqui, W.J., et al., Anti-thrombotic therapy strategies with long-term 
anticoagulation after percutaneous coronary intervention - a systematic review and 
meta-analysis. J Community Hosp Intern Med Perspect, 2019. 9(3): p. 203-210. 
 
76. Gong, X., et al., Antithrombotic therapy strategies for atrial fibrillation patients 
undergoing percutaneous coronary intervention: A systematic review and network 
meta-analysis. PLoS One, 2017. 12(10): p. e0186449. 
 
77 . Roule, V., et al., Vitamin K antagonist vs direct oral anticoagulants with antiplatelet 
therapy in dual or triple therapy after percutaneous coronary intervention or acute 
coronary syndrome in atrial fibrillation: Meta-analysis of randomized controlled 
trials. Clin Cardiol, 2019. 
 
78. Farid, N.A., et al., Cytochrome P450 3A inhibition by ketoconazole affects prasugrel 
and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol 
Ther, 2007. 81(5): p. 735-41. 
 51 
79. Sherwood, M.W., et al., Use of Dual Antiplatelet Therapy and Patient Outcomes in 
Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. 
JACC: Cardiovascular Interventions, 2016. 
 
80. Kopin, D., et al., Percutaneous coronary intervention and antiplatelet therapy in 
patients with atrial fibrillation receiving apixaban or warfarin: Insights from the 
ARISTOTLE trial. Am Heart J, 2018. 197: p. 133-141. 
 
81. Kumar, S., et al., Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet 
Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of 
Randomized Controlled Trials. Cardiol Rev, 2016. 24(5): p. 218-23. 
 
82. Lip, G.Y., et al., Assessing the risk of bleeding in patients with atrial fibrillation: the 
Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol, 2012. 5(5): p. 
941-8. 
 
83. Martinez-Rubio, A. and R. Martinez-Torrecilla, Current evidence for new oral 
anticoagulants in the treatment of nonvalvular atrial fibrillation: comparison of 
substudies. Rev Esp Cardiol (Engl Ed), 2015. 68(3): p. 185-9. 
 
84. Hohnloser, S.H., et al., Myocardial ischemic events in patients with atrial fibrillation 
treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-
Term Anticoagulation Therapy) trial. Circulation, 2012. 125(5): p. 669-76. 
 
85. Lee, C.J., et al., Risk of Myocardial Infarction in Anticoagulated Patients With Atrial 
Fibrillation. J Am Coll Cardiol, 2018. 72(1): p. 17-26. 
 
86. Hohnloser, S.H. and J.W. Eikelboom, Direct Oral Anticoagulants and 
Myocardial Infarction. Journal of the American College of Cardiology, 2018. 72: p. 
27-28. 
 
87. Sherwood, M.W., et al., Outcomes of temporary interruption of rivaroxaban 
compared with warfarin in patients with nonvalvular atrial fibrillation: results from 
the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K 
antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET 
AF). Circulation, 2014. 129(18): p. 1850-9. 
 
88. Larsen, T.B., et al., Bleeding events among new starters and switchers to dabigatran 
compared with warfarin in atrial fibrillation. American Journal of Medicine, 2014. 
 
89. Reilly, P.A., et al., The effect of dabigatran plasma concentrations and patient 
characteristics on the frequency of ischemic stroke and major bleeding in atrial 
fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term 
Anticoagulation Therapy). J Am Coll Cardiol, 2014. 63(4): p. 321-8. 
 
90. Bennaghmouch, N., et al., Efficacy and safety of the use of non-Vitamin K antagonist 
oral anticoagulants in patients with nonvalvular atrial fibrillation and concomitant 




91. Gaubert, M., et al., Dabigatran versus vitamin k antagonist: an observational across-
cohort comparison in acute coronary syndrome patients with atrial fibrillation. J 
Thromb Haemost, 2018. 16(3): p. 465-473. 
 
92. Stettler, C., et al., Outcomes associated with drug-eluting and bare-metal stents: a 
collaborative network meta-analysis. Lancet, 2007. 370(9591): p. 937-48. 
 
93. Johnson, J.A., et al., Clinical Pharmacogenetics Implementation Consortium 
Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol 
Ther, 2011. 90(4): p. 625-9. 
 
94. Kip, K.E., et al., The problem with composite end points in cardiovascular studies: the 
story of major adverse cardiac events and percutaneous coronary intervention. J Am 
Coll Cardiol, 2008. 51(7): p. 701-7. 
 
95. Borenstein, M., et al., Fixed-Effect Versus Random-Effects Models, in Introduction to 
Meta-Analysis. 2009. 
 
96. Zelniker, T.A., et al., The efficacy and safety of non-vitamin K antagonist oral 
anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-
analysis of randomized trials. Eur Heart J Acute Cardiovasc Care, 2018: p. 
2048872618796990. 
 
97. Chandrasekhar, J., et al., Antithrombotic strategy variability in ATrial fibrillation and 
obstructive coronary disease revascularized with PCI-rationale and study design of 
the prospective observational multicenter AVIATOR 2 registry. Am Heart J, 2015. 
170(6): p. 1234-42. 
 
98. Gao, F., et al., Rationale and design of the RT-AF study: Combination of rivaroxaban 
and ticagrelor in patients with atrial fibrillation and coronary artery disease 
undergoing percutaneous coronary intervention. Contemp Clin Trials, 2015. 43: p. 
129-32. 
 
99.       Han, S., et al., The treatment pattern and adherence to direct oral anticoagulants in 
patients with atrial fibrillation aged over 65. PLoS One, 2019. 14(4): p. e0214666. 
 
100. Zhou, M., et al., Adherence to a novel oral anticoagulant among patients with atrial 
fibrillation. Journal of Managed Care Pharmacy, 2015. 
 
101. Beyer-Westendorf, J., B. Ehlken, and T. Evers, Real-world persistence and adherence 
to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. 




 SUPPLEMENTARY MATERIAL 
SEARCH STRATEGY 
Databases: 
1) PUBMED  ADVANCED SEARCH STRATEGY 
 
PLATELET AGGREGATION INHIBITORS 
(((((((((((((((((((((((((((((((((((((aspirin[MeSH Terms])) OR (2- AND (Acetyloxy) AND benzoic Acid)) 
OR (Acetylsalicylic Acid)) OR (Acetysal)) OR (Acylpyrin)) OR (Aloxiprimum)) OR (Colfarit)) OR 
(Dispril)) OR (Easprin)) OR (Ecotrin)) OR (Endosprin)) OR (Magnecyl)) OR (Micristin)) OR 
(Polopirin)) OR (Polopiryna)) OR (Solprin)) OR (Solupsan)) OR (Zorprin))) OR 
(((((((((((((dipyridamole[MeSH Terms])) OR (Antistenocardin)) OR (Apo-Dipyridamole)) OR 
(Cerebrovase)) OR (Cleridium)) OR (Curantil)) OR (Curantyl)) OR (Kurantil)) OR (Miosen)) OR 
(Novo-Dipiradol)) OR (Persantin)) OR (Persantine))) OR ((((triflusal)) OR (2-acetoxy-4-
trifluoromethylbenzoic acid)) OR (Disgren))) OR (((((((((((((((((clopidogrel)) OR (clopidogrel 
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(clopidogrel besylate)) OR (clopidogrel besilate)) OR (clopidogrel hydrochloride)) OR (clopidogrel 
Sandoz)) OR (clopidogrel bisulfate)) OR (Plavix))) OR (((((((((((Prasugrel Hydrochloride[MeSH 
Terms])) OR (Prasugrel HCl)) OR (Prasugrel)) OR (CS 747)) OR (CS-747)) OR (LY 640315)) OR 
(LY-640315)) OR (LY640315)) OR (Effient)) OR (Efient))) OR ((((((((Ticagrelor)) OR (3- AND (7- 
AND ((2- AND (3,4-difluorophenyl) AND cyclopropyl) AND amino) AND -5- AND (propylthio) 
AND -3H- AND (1-3) AND -triazolo AND (4,5-d) AND pyrimidin-3-yl) AND -5- AND (2-
hydroxyethoxy) AND cyclopentane-1,2-diol)) OR (AZD 6140)) OR (AZD-6140)) OR (AZD6140)) 
OR (Brilinta)) OR (Brilique))) OR (((((((((Ticlopidine[MeSH Terms])) OR (Ticlopidine 
Hydrochloride)) OR (Ticlodix)) OR (Ticlodone)) OR (Ticlid)) OR (53-32C)) OR (53 32C)) OR 
(5332C))) OR (((((((cilostazol)) OR (2 AND (1H) AND -quinolinone, 6- AND (4- AND (1-
cyclohexyl-1H-tetrazol-5-yl) AND butoxy) AND -3,4-dihydro-)) OR (6- AND (4- AND (1-
cyclohexyl-1H-tetrazol-5-yl) AND butoxy) AND -3,4-dihydro-2 AND (1H) AND -quinolinone)) OR 
(OPC 13013)) OR (OPC-13013)) OR (Pletal))) OR ((((((vorapaxar)) OR (Zontivity)) OR (SCH 
530348)) OR (SCH530348)) OR (SCH-530348))) OR (((((((abciximab)) OR (c7E3 Fab)) OR 
(chimeric 7E3 Fab)) OR (Clotinab)) OR (ReoPro)) OR (CentoRx))) OR ((((((eptifibatide)) OR 
(epifibatide)) OR (epifibratide)) OR (Integrilin)) OR (Integrelin))) OR ((((((((((((tirofiban)) OR (N- 
AND (butylsulfonyl) AND -O- AND (4- AND (4-piperidyl) AND butyl) AND -L-tyrosine)) OR (MK 
383)) OR (MK-383)) OR (tirofiban hydrochloride)) OR (tirofiban hydrochloride monohydrate)) OR 
(Aggrastat)) OR (Agrastat)) OR (L 700462)) OR (L-700462)) OR (L-700,462))) OR (((((cangrelor)) 
OR (Kengreal)) OR (AR C69931MX)) OR (AR-C69931MX))) OR ((((((((((Platelet Aggregation 
Inhibitors[MeSH Terms])) OR (Platelet Antiaggregants)) OR (Antiplatelet Agents)) OR (Antiplatelet 
Drugs)) OR (Blood Platelet Aggregation Inhibitors)) OR (Blood Platelet Antagonists)) OR (Blood 
Platelet Antiaggregants)) OR (Platelet Antagonists)) OR (Platelet Inhibitors))) OR ((((((((((Purinergic 
P2Y Receptor Antagonists[MeSH Terms])) OR (ADP Receptor Antagonists)) OR (ADP Receptor 
Blockers)) OR (Adenosine Diphosphate Receptor Antagonists)) OR (P2Y Purinoceptor Antagonists)) 
OR (P2Y1 Purinoceptor Antagonists)) OR (P2Y12 Purinoceptor Antagonists)) OR (P2Y12 Receptor 




DIRECT ORAL ANTICOAGULANTS 
(((((((((((Rivaroxaban[MeSH Terms])) OR (5-chloro-N- AND (((5S) AND -2-oxo-3- AND 
(4- AND (3-oxomorpholin-4-yl) AND phenyl) AND -1,3-oxazolidin-5-yl) AND methyl) 
AND thiophene-2-carboxamide)) OR (Xarelto)) OR (BAY 59-7939)) OR (BAY 59 7939)) 
OR (BAY 597939))) OR (((((((Dabigatran[MeSH Terms])) OR (BIBR 953)) OR (BIBR 
1048)) OR (Dabigatran Etexilate)) OR (Dabigatran Etexilate Mesylate)) OR (Pradaxa))) OR 
(((((apixaban)) OR (BMS 562247)) OR (BMS562247)) OR (BMS-562247))) OR 
(((((edoxaban)) OR (DU-176b)) OR (DU-176)) OR (edoxaban tosylate))) OR 
(((((betrixaban)) OR (N- AND (5-chloropyridin-2-yl) AND -2- AND (4- AND (N, N-




PATHOLOGIES AND INTERVENTIONS 
(((((((((((((((((((((((((((((((((((((((((((Atrial Fibrillation[MeSH Terms])) OR (Auricular 
Fibrillation)) OR (Familial Atrial Fibrillation)) OR (Paroxysmal Atrial Fibrillation)) OR 
(Persistent Atrial Fibrillation)) OR (myocardial ischemia[MeSH Terms])) OR (Ischemic Heart 
Disease)) OR (acute coronary syndrome[MeSH Terms])) OR (atrial flutter[MeSH Terms])) 
OR (Auricular Flutter)) OR (Angina Pectoris[MeSH Terms])) OR (Angor Pectoris)) OR 
(Stenocardia)) OR (coronary disease[MeSH Terms])) OR (Coronary Heart Disease)) OR 
(myocardial infarction[MeSH Terms])) OR (Cardiovascular Stroke)) OR (Heart Attack)) OR 
(Myocardial Infarct)) OR (Stroke[MeSH Terms])) OR (Apoplexy)) OR (CVA AND 
(Cerebrovascular Accident))) OR (Cerebral Stroke)) OR (Cerebrovascular Accident)) OR 
(Acute Cerebrovascular Accident)) OR (Cerebrovascular Apoplexy)) OR (Cerebrovascular 
Stroke)) OR (Acute Stroke)) OR (Brain Vascular Accident)) OR (Thrombosis[MeSH 
Terms])) OR (Blood Clot)) OR (Thrombus)) OR (Thromboembolism[MeSH Terms])) OR 
(Hemorrhage[MeSH Terms])) OR (Bleeding)) OR (Arteriosclerosis[MeSH Terms])) OR 
(Angioplasty[MeSH Terms])) OR (Transluminal Angioplasty)) OR (Endoluminal Repair)) 
OR (Percutaneous Transluminal Angioplasty)) OR (Percutaneous Coronary 









Complete search  (Search results - 773 articles) 
((((((((((((((((((((((((((((((((((((aspirin[MeSH Terms])) OR (2- AND (Acetyloxy) AND benzoic Acid)) OR (Acetylsalicylic 
Acid)) OR (Acetysal)) OR (Acylpyrin)) OR (Aloxiprimum)) OR (Colfarit)) OR (Dispril)) OR (Easprin)) OR (Ecotrin)) 
OR (Endosprin)) OR (Magnecyl)) OR (Micristin)) OR (Polopirin)) OR (Polopiryna)) OR (Solprin)) OR (Solupsan)) 
OR (Zorprin))) OR (((((((((((((dipyridamole[MeSH Terms])) OR (Antistenocardin)) OR (Apo-Dipyridamole)) OR 
(Cerebrovase)) OR (Cleridium)) OR (Curantil)) OR (Curantyl)) OR (Kurantil)) OR (Miosen)) OR (Novo-Dipiradol)) 
OR (Persantin)) OR (Persantine))) OR ((((triflusal)) OR (2-acetoxy-4-trifluoromethylbenzoic acid)) OR (Disgren))) 
OR (((((((((((((((((clopidogrel)) OR (clopidogrel napadisilate)) OR (clopidogrel, AND (S) AND -isomer)) OR (Iscover)) 
OR (PCR 4099)) OR (PCR-4099)) OR (clopidogrel-Mepha)) OR (SC 25989C)) OR (SC 25990C)) OR (SR 25989)) OR 
(clopidogrel besylate)) OR (clopidogrel besilate)) OR (clopidogrel hydrochloride)) OR (clopidogrel Sandoz)) OR 
(clopidogrel bisulfate)) OR (Plavix))) OR (((((((((((Prasugrel Hydrochloride[MeSH Terms])) OR (Prasugrel HCl)) OR 
(Prasugrel)) OR (CS 747)) OR (CS-747)) OR (LY 640315)) OR (LY-640315)) OR (LY640315)) OR (Effient)) OR 
(Efient))) OR ((((((((Ticagrelor)) OR (3- AND (7- AND ((2- AND (3,4-difluorophenyl) AND cyclopropyl) AND amino) 
AND -5- AND (propylthio) AND -3H- AND (1-3) AND -triazolo AND (4,5-d) AND pyrimidin-3-yl) AND -5- AND (2-
hydroxyethoxy) AND cyclopentane-1,2-diol)) OR (AZD 6140)) OR (AZD-6140)) OR (AZD6140)) OR (Brilinta)) OR 
(Brilique))) OR (((((((((Ticlopidine[MeSH Terms])) OR (Ticlopidine Hydrochloride)) OR (Ticlodix)) OR (Ticlodone)) 
OR (Ticlid)) OR (53-32C)) OR (53 32C)) OR (5332C))) OR (((((((cilostazol)) OR (2 AND (1H) AND -quinolinone, 6- 
AND (4- AND (1-cyclohexyl-1H-tetrazol-5-yl) AND butoxy) AND -3,4-dihydro-)) OR (6- AND (4- AND (1-cyclohexyl-
1H-tetrazol-5-yl) AND butoxy) AND -3,4-dihydro-2 AND (1H) AND -quinolinone)) OR (OPC 13013)) OR (OPC-
13013)) OR (Pletal))) OR ((((((vorapaxar)) OR (Zontivity)) OR (SCH 530348)) OR (SCH530348)) OR (SCH-530348))) 
OR (((((((abciximab)) OR (c7E3 Fab)) OR (chimeric 7E3 Fab)) OR (Clotinab)) OR (ReoPro)) OR (CentoRx))) OR 
((((((eptifibatide)) OR (epifibatide)) OR (epifibratide)) OR (Integrilin)) OR (Integrelin))) OR ((((((((((((tirofiban)) OR 
(N- AND (butylsulfonyl) AND -O- AND (4- AND (4-piperidyl) AND butyl) AND -L-tyrosine)) OR (MK 383)) OR 
(MK-383)) OR (tirofiban hydrochloride)) OR (tirofiban hydrochloride monohydrate)) OR (Aggrastat)) OR 
(Agrastat)) OR (L 700462)) OR (L-700462)) OR (L-700,462))) OR (((((cangrelor)) OR (Kengreal)) OR (AR 
C69931MX)) OR (AR-C69931MX))) OR ((((((((((Platelet Aggregation Inhibitors[MeSH Terms])) OR (Platelet 
Antiaggregants)) OR (Antiplatelet Agents)) OR (Antiplatelet Drugs)) OR (Blood Platelet Aggregation Inhibitors)) OR 
(Blood Platelet Antagonists)) OR (Blood Platelet Antiaggregants)) OR (Platelet Antagonists)) OR (Platelet 
Inhibitors))) OR ((((((((((Purinergic P2Y Receptor Antagonists[MeSH Terms])) OR (ADP Receptor Antagonists)) OR 
(ADP Receptor Blockers)) OR (Adenosine Diphosphate Receptor Antagonists)) OR (P2Y Purinoceptor Antagonists)) 
OR (P2Y1 Purinoceptor Antagonists)) OR (P2Y12 Purinoceptor Antagonists)) OR (P2Y12 Receptor Antagonists)) OR 
(Purinergic P2Y12 Receptor Antagonists)))) AND ((((((((((((Rivaroxaban[MeSH Terms])) OR (5-chloro-N- AND (((5S) 
AND -2-oxo-3- AND (4- AND (3-oxomorpholin-4-yl) AND phenyl) AND -1,3-oxazolidin-5-yl) AND methyl) AND 
thiophene-2-carboxamide)) OR (Xarelto)) OR (BAY 59-7939)) OR (BAY 59 7939)) OR (BAY 597939))) OR 
(((((((Dabigatran[MeSH Terms])) OR (BIBR 953)) OR (BIBR 1048)) OR (Dabigatran Etexilate)) OR (Dabigatran 
Etexilate Mesylate)) OR (Pradaxa))) OR (((((apixaban)) OR (BMS 562247)) OR (BMS562247)) OR (BMS-562247))) 
OR (((((edoxaban)) OR (DU-176b)) OR (DU-176)) OR (edoxaban tosylate))) OR (((((betrixaban)) OR (N- AND (5-
chloropyridin-2-yl) AND -2- AND (4- AND (N, N-dimethylcarbamimidoyl) AND benzamido) AND -5-
methoxybenzamide)) OR (BEVYXXA)) OR (PRT054021)))) AND ((((((((((((((((((((((((((((((((((((((((((((Atrial 
Fibrillation[MeSH Terms])) OR (Auricular Fibrillation)) OR (Familial Atrial Fibrillation)) OR (Paroxysmal Atrial 
Fibrillation)) OR (Persistent Atrial Fibrillation)) OR (myocardial ischemia[MeSH Terms])) OR (Ischemic Heart 
Disease)) OR (acute coronary syndrome[MeSH Terms])) OR (atrial flutter[MeSH Terms])) OR (Auricular Flutter)) 
OR (Angina Pectoris[MeSH Terms])) OR (Angor Pectoris)) OR (Stenocardia)) OR (coronary disease[MeSH Terms])) 
OR (Coronary Heart Disease)) OR (myocardial infarction[MeSH Terms])) OR (Cardiovascular Stroke)) OR (Heart 
Attack)) OR (Myocardial Infarct)) OR (Stroke[MeSH Terms])) OR (Apoplexy)) OR (CVA AND (Cerebrovascular 
Accident))) OR (Cerebral Stroke)) OR (Cerebrovascular Accident)) OR (Acute Cerebrovascular Accident)) OR 
(Cerebrovascular Apoplexy)) OR (Cerebrovascular Stroke)) OR (Acute Stroke)) OR (Brain Vascular Accident)) OR 
(Thrombosis[MeSH Terms])) OR (Blood Clot)) OR (Thrombus)) OR (Thromboembolism[MeSH Terms])) OR 
(Hemorrhage[MeSH Terms])) OR (Bleeding)) OR (Arteriosclerosis[MeSH Terms])) OR (Angioplasty[MeSH Terms])) 
OR (Transluminal Angioplasty)) OR (Endoluminal Repair)) OR (Percutaneous Transluminal Angioplasty)) OR 






2) SCOPUS ( Search results – 787 articles ) 
TITLE-ABS("aspirin") OR TITLE-ABS("Acetylsalicylic Acid") OR TITLE-ABS("Acetysal") OR TITLE-ABS("Acylpyrin") 
OR TITLE-ABS("Aloxiprimum") OR TITLE-ABS("Colfarit") OR TITLE-ABS("Dispril") OR TITLE-ABS("Easprin") OR 
TITLE-ABS("Ecotrin") OR TITLE-ABS("Endosprin") OR TITLE-ABS("Magnecyl") OR TITLE-ABS("Micristin") OR 
TITLE-ABS("Polopirin") OR TITLE-ABS("Polopiryna") OR TITLE-ABS("Solprin") OR TITLE-ABS("Solupsan") OR 
TITLE-ABS("Zorprin") OR TITLE-ABS("dipyridamole") OR TITLE-ABS("Antistenocardin") OR TITLE-ABS("Apo-
Dipyridamole") OR TITLE-ABS("Cerebrovase") OR TITLE-ABS("Curantil") OR TITLE-ABS("Curantyl") OR TITLE-
ABS("Kurantil") OR TITLE-ABS("Miosen") OR TITLE-ABS("Novo-Dipiradol") OR TITLE-ABS("Persantin") OR TITLE-
ABS("Persantine") OR TITLE-ABS("triflusal") OR TITLE-ABS("Disgren") OR TITLE-ABS("clopidogrel") OR TITLE-
ABS("clopidogrel napadisilate") OR TITLE-ABS("Iscover") OR TITLE-ABS("PCR 4099") OR TITLE-ABS("PCR-4099") 
OR TITLE-ABS("clopidogrel-Mepha") OR TITLE-ABS("SC 25989C") OR TITLE-ABS("SC 25990C") OR TITLE-
ABS("SR 25989") OR TITLE-ABS("clopidogrel besylate") OR TITLE-ABS("clopidogrel besilate") OR TITLE-
ABS("clopidogrel hydrochloride") OR TITLE-ABS("clopidogrel Sandoz") OR TITLE-ABS("clopidogrel bisulfate") OR 
TITLE-ABS("Plavix") OR TITLE-ABS("Prasugrel Hydrochloride") OR TITLE-ABS("Prasugrel HCl") OR TITLE-
ABS("Prasugrel") OR TITLE-ABS("CS 747") OR TITLE-ABS("CS-747") OR TITLE-ABS("LY 640315") OR TITLE-
ABS("LY-640315") OR TITLE-ABS("LY640315") OR TITLE-ABS("Effient") OR TITLE-ABS("Efient") OR TITLE-
ABS("Ticagrelor") OR TITLE-ABS("AZD 6140") OR TITLE-ABS("AZD-6140") OR TITLE-ABS("AZD6140") OR 
TITLE-ABS("Brilinta") OR TITLE-ABS("Brilique") OR TITLE-ABS ("Ticlopidine") OR TITLE-ABS("Ticlopidine 
Hydrochloride") OR TITLE-ABS("Ticlodix") OR TITLE-ABS("Ticlodone") OR TITLE-ABS("Ticlid") OR TITLE-
ABS("53-32C") OR TITLE-ABS("53 32C") OR TITLE-ABS("5332C") OR TITLE-ABS("cilostazol") OR TITLE-
ABS("OPC 13013") OR TITLE-ABS("OPC-13013") OR TITLE-ABS("Pletal") OR TITLE-ABS("vorapaxar") OR TITLE-
ABS("Zontivity") OR TITLE-ABS("SCH 530348") OR TITLE-ABS("SCH530348") OR TITLE-ABS("SCH-530348") OR 
TITLE-ABS("abciximab") OR TITLE-ABS("c7E3 Fab") OR TITLE-ABS("chimeric 7E3 Fab") OR TITLE-ABS("Clotinab") 
OR TITLE-ABS("ReoPro") OR TITLE-ABS("CentoRx") OR TITLE-ABS("eptifibatide") OR TITLE-ABS("epifibatide") 
OR TITLE-ABS("epifibratide") OR TITLE-ABS("Integrilin") OR TITLE-ABS("Integrelin") OR TITLE-ABS("tirofiban") 
OR TITLE-ABS("MK 383") OR TITLE-ABS("MK-383") OR TITLE-ABS("tirofiban hydrochloride") OR TITLE-
ABS("tirofiban hydrochloride monohydrate") OR TITLE-ABS("Aggrastat") OR TITLE-ABS("Agrastat") OR TITLE-
ABS("L 700462") OR TITLE-ABS("L-700462") OR TITLE-ABS("L-700,462") OR TITLE-ABS("cangrelor") OR TITLE-
ABS("Kengreal") OR TITLE-ABS("AR C69931MX") OR TITLE-ABS("AR-C69931MX") OR INDEXTERMS("Platelet 
Aggregation Inhibitors") OR ALL("Platelet Antiaggregants") OR ALL("Antiplatelet Agents") OR ALL("Antiplatelet 
Drugs") OR ALL("Blood Platelet Aggregation Inhibitors") OR ALL("Blood Platelet Antagonists") OR ALL("Blood Platelet 
Antiaggregants") OR ALL("Platelet Antagonists") OR ALL("Platelet Inhibitors") OR INDEXTERMS("Purinergic P2Y 
Receptor Antagonists") OR ALL("ADP Receptor Antagonists") OR ALL("ADP Receptor Blockers") OR ALL("Adenosine 
Diphosphate Receptor Antagonists") OR ALL("P2Y Purinoceptor Antagonists") OR ALL("P2Y1 Purinoceptor Antagonists") 
OR ALL("P2Y12 Purinoceptor Antagonists") OR ALL("P2Y12 Receptor Antagonists") OR ALL("Purinergic P2Y12 
Receptor Antagonists") AND TITLE-ABS("Rivaroxaban") OR TITLE-ABS("Xarelto") OR TITLE-ABS("BAY 59-7939") 
OR TITLE-ABS("BAY 59 7939") OR TITLE-ABS("BAY 597939") OR TITLE-ABS("Dabigatran") OR TITLE-
ABS("BIBR 953") OR TITLE-ABS("BIBR 1048") OR TITLE-ABS("Dabigatran Etexilate") OR TITLE-ABS("Dabigatran 
Etexilate Mesylate") OR TITLE-ABS("Pradaxa") OR TITLE-ABS("apixaban") OR TITLE-ABS("BMS 562247") OR 
TITLE-ABS("BMS562247") OR TITLE-ABS("BMS-562247") OR TITLE-ABS("edoxaban") OR TITLE-ABS("DU-176b") 
OR TITLE-ABS("DU-176") OR TITLE-ABS("edoxaban tosylate") OR TITLE-ABS("betrixaban") OR TITLE-
ABS("BEVYXXA") OR TITLE-ABS("PRT054021") AND INDEXTERMS("Atrial Fibrillation") OR ALL("Auricular 
Fibrillation") OR ALL("Familial Atrial Fibrillation") OR ALL("Paroxysmal Atrial Fibrillation") OR ALL("Persistent Atrial 
Fibrillation") OR INDEXTERMS("myocardial ischemia") OR ALL("Ischemic Heart Disease") OR INDEXTERMS("acute 
coronary syndrome") OR INDEXTERMS("atrial flutter") OR ALL("Auricular Flutter") OR INDEXTERMS("Angina 
Pectoris") OR ALL("Angor Pectoris") OR ALL("Stenocardia") OR INDEXTERMS("coronary disease") OR ALL("Coronary 
Heart Disease") OR INDEXTERMS("myocardial infarction") OR ALL("Cardiovascular Stroke") OR ALL("Heart Attack") 
OR ALL("Myocardial Infarct") OR INDEXTERMS("Stroke") OR ALL("Apoplexy") OR ALL("Cerebral Stroke") OR 
ALL("Cerebrovascular Accident") OR ALL("Acute Cerebrovascular Accident") OR ALL("Cerebrovascular Apoplexy") OR 
ALL("Cerebrovascular Stroke") OR ALL("Acute Stroke") OR ALL("Brain Vascular Accident") OR 
INDEXTERMS("Thrombosis") OR ALL("Blood Clot") OR ALL("Thrombus") OR INDEXTERMS("Thromboembolism") 
OR INDEXTERMS("Hemorrhage") OR ALL("Bleeding") OR INDEXTERMS("Arteriosclerosis") OR 
INDEXTERMS("Angioplasty") OR ALL("Transluminal Angioplasty") OR ALL("Endoluminal Repair") OR 
INDEXTERMS("Percutaneous Transluminal Angioplasty") OR ALL("Percutaneous Coronary Intervention") OR 
ALL("Percutaneous Coronary Revascularization") OR INDEXTERMS("Stents") 
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3) COCHRANE LIBRARY (Search results – 405 articles) 
 
ID Search Hits 
#1) MeSH descriptor: [Aspirin] explode all trees (5635) 
#2) 2- (Acetyloxy) benzoic Acid  (5) 
#3) Acetylsalicylic Acid  (6609) 
#4) Acetysal  (4) 
#5) Acylpyrin  (4) 
#6) Aloxiprimum  (3) 
#7) Colfarit  (11) 
#8) Dispril  (13) 
#9) Easprin (3) 
#10) Ecotrin  (10) 
#11) Endosprin  (4) 
#12) Magnecyl  (7) 
#13) Micristin  (11) 
#14) Polopirin  (4) 
#15) Polopiryna  (5) 
#16) Solprin (4) 
#17) Solupsan  (6) 
#18) Zorprin  (4) 
#19) #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or 
#17 or #18  (11075) 
#20) MeSH descriptor: [Dipyridamole] explode all trees (645) 
#21) Antistenocardin  (4) 
#22) Apo-Dipyridamole  (0) 
#23) Cerebrovase  (1) 
#24) Cléridium  (1) 
#25) Curantil  (4) 
#26) Curantyl  (8) 
#27) Kurantil  (5) 
#28) Miosen  (1) 
#29) Novo-Dipiradol  (1) 
#30) Persantin  (58) 
#31) Persantine  (43) 
#32) #20 or #21 or 22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31  (125136) 
#33) triflusal  (140) 
#34) 2 acetoxy 4 trifluoromethylbenzoic acid  (0) 
#35) disgren  (11) 
#36) #33 or #34 or #35  (140) 
#37) clopidogrel  (4729) 
#38) clopidogrel napadisilate  (4) 
#39) clopidogrel isomer  (6) 
#40) Iscover  (6) 
#41) PCR 4099  (2) 
#42) PCR-4099  (1) 
#43) clopidogrel-Mepha  (1) 
#44) SC 25989C  (0) 
#45) SC 25990C  (0) 
#46) SR 25989  (1) 
#47) clopidogrel besylate  (15) 
#48) clopidogrel besilate  (0) 
#49) clopidogrel hydrochloride  (243) 
#50) clopidogrel Sandoz  (4) 
#51) clopidogrel bisulfate  (42) 
#52) Plavix  (116) 
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#53) #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 
or #52  (4739) 
#54) MeSH descriptor: [Prasugrel Hydrochloride] explode all trees (312) 
#55) Prasugrel HCl  (0) 
#56) Prasugrel  (915) 
#57) CS 747  (43) 
#58) CS-747  (11) 
#59) LY 640315  (0) 
#60) LY-640315  (0) 
#61) LY640315  (8) 
#62) Effient  (14) 
#63) Efient  (14) 
#64) #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63  (948) 
#65) Ticagrelor  (1122) 
#66) 3- (7- ((2- (3,4-difluorophenyl) cyclopropyl) amino) -5- (propylthio) -3H- (1-3) -triazolo (4,5-d) 
pyrimidin-3-yl) -5- (2-hydroxyethoxy) cyclopentane-1,2-diol  (0) 
#67) AZD 6140  (2) 
#68) AZD6140  (31) 
#69) AZD-6140  (2) 
#70) Brilinta  (17) 
#71) Brilique  (6) 
#72) #65 or #66 or #67 or #68 or #69 or #70 or #71  (1128) 
#73) MeSH descriptor: [Ticlopidine] explode all trees (1916) 
#74) Ticlopidine Hydrochloride  (230) 
#75) Ticlodix  (2) 
#76) Ticlodone  (3) 
#77) Ticlid  (34) 
#78) 53-32C  (0) 
#79) 53 32C  (1) 
#80) 5332C  (0) 
#81) #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80  (1968) 
#82) Cilostazol  (719) 
#83) 2 (1H) -quinolinone, 6- (4- (1-cyclohexyl-1H-tetrazol-5-yl) butoxy) -3,4-dihydro-  (3) 
#84) 6- (4- (1-cyclohexyl-1H-tetrazol-5-yl) butoxy) -3,4-dihydro-2 (1H) -quinolinone  (3) 
#85) OPC 13013  (15) 
#86) OPC-13013  (15) 
#87) Pletal  (32) 
#88) #82 or #83 or #84 or #85 or #86 or #87  (724) 
#89) vorapaxar  (128) 
#90) Zontivity  (2) 
#91) SCH 530348  (34) 
#92) SCH530348  (8) 
#93) SCH-530348  (34) 
#94) #89 or #90 or #91 or #92 or #93  (137) 
#95) Abciximab  (874) 
#96) c7E3 Fab  (47) 
#97) chimeric 7E3 Fab  (6) 
#98) Clotinab  (3) 
#99) ReoPro   (91) 
#100) CentoRx  (0) 
#101) #95 or #96 or #97 or #98 or #99 or #100  (920) 
#102)) Eptifibatide  (410) 
#103) Epifibatide  (2) 
#104) Epifibratide  (0) 
#105) Integrilin  (108) 
#106) Integrelin  (12) 
#107) #102 or #103 or #104 or #105 or #106  (432) 
#108) Tirofiban  (539) 
#109) N- (butylsulfonyl) -O- (4- (4-piperidyl) butyl) -L-tyrosine  (0) 
#110) MK 383  (47) 
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#111) MK-383  (7) 
#112) Tirofiban hydrochloride  (9) 
#113) Tirofiban hydrochloride monohydrate  (0) 
#114) Aggrastat  (45) 
#115) Agrastat  (0) 
#116) L 700462  (0) 
#117) L-700462  (0) 
#118) L-700,462  (2) 
#119) #108 or #109 or #110 or #111 or #112 or #113 or #114 or #115 or #116 or #117 or #118  (595) 
#120) Cangrelor  (104) 
#121) Kengreal  (1) 
#122) AR C69931MX  (5) 
#123) AR-C69931MX  (5) 
#124) #120 or #121 or #122 or #123  (107) 
#125) MeSH descriptor: [Platelet Aggregation Inhibitors] explode all trees (3949) 
#126) Platelet Antiaggregants  (22) 
#127) Antiplatelet Agents  (1192) 
#128) Antiplatelet drugs  (900) 
#129) Blood Platelet Aggregation Inhibitors  (2009) 
#130) Blood Platelet Antagonists  (948) 
#131) Blood Platelet Antiaggregants  (10) 
#132) Platelet Antagonists  (1760) 
#133) Platelet Inhibitors  (5457) 
#134) #125 or #126 or #127 or #128 or #129 or #130 or #131 or #132 or #133  (6739) 
#135) MeSH descriptor: [Purinergic P2Y Receptor Antagonists] explode all trees (278) 
#136) ADP Receptor Antagonists  (108) 
#137) Adenosine Diphosphate Receptor Antagonists  (115) 
#138) P2Y Purinoceptor Antagonists  (0) 
#139) P2Y1 Purinoceptor Antagonists  (0) 
#140) P2Y12 Purinoceptor Antagonists  (0) 
#141) P2Y12 Receptor Antagonists  (207) 
#142) Purinergic P2Y12 Receptor Antagonists  (180) 
#143) #135 or #136 or #137 or #138 or #139 or #140 or #141 or #142  (458) 
#144) #19 or #32 or #36 or #53 or #64 or #72 or #81 or #88 or #94 or #101 or #107 or #119 or #124 or #134 
or #143  (140264) 
#145) MeSH descriptor: [Rivaroxaban] explode all trees (317) 
#146) 5-chloro-N- (((5S) -2-oxo-3- (4- (3-oxomorpholin-4-yl) phenyl) -1,3-oxazolidin-5-yl) methyl) 
thiophene-2-carboxamide  (0) 
#147) Xarelto  (34) 
#148) BAY 59-7939  (35) 
#149) BAY 59 7939  (35) 
#150) BAY 597939  (8) 
#151) #145 or #146 or #147 or #148 or #149 or #150  (356) 
#152) MeSH descriptor: [Dabigatran] explode all trees (235) 
#153) BIBR 953  (22) 
#154) BIBR 1048  (35) 
#155) Dabigatran Etexilate  (255) 
#156) Dabigatran Etexilate Mesylate  (2) 
#157) Pradaxa  (31) 
#158) #152 or #153 or #154 or #155 or #156 or #157  (408) 
#159) apixaban  (731) 
#160) BMS 562247  (10) 
#161) BMS562247  (0) 
#162) BMS-562247  (10) 
#163) #159 or #160 or #161 or #162  (731) 
#164) edoxaban  (396) 
#165) DU-176b  (40) 
#166) DU-176  (3) 
#167) edoxaban tosylate  (5) 
#168) #164 or #165 or #166 or #167  (412) 
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#169) betrixaban  (100) 
#170) N- (5-chloropyridin-2-yl) -2- (4- (N,N-dimethylcarbamimidoyl) benzamido) -5-methoxybenzamide 
 (0) 
#171) Bevyxxa  (0) 
#172) PRT054021  (9) 
#173) #169 or #170 or #171 or #172  (102) 
#174) #151 or #158 or #163 or #168 or #173  (1708) 
#175) MeSH descriptor: [Atrial Fibrillation] explode all trees (4304) 
#176) Auricular Fibrillation  (72) 
#177) Familial Atrial Fibrillation  (34) 
#178) Paroxysmal Atrial Fibrillation  (1577) 
#179) Persistent Atrial Fibrillation  (1269) 
#180) MeSH descriptor: [Myocardial Ischemia] explode all trees (27812) 
#181) Ischemic Heart Disease  (6426) 
#182) MeSH descriptor: [Acute Coronary Syndrome] explode all trees (1712) 
#183) MeSH descriptor: [Atrial Flutter] explode all trees (347) 
#184) Auricular Flutter  (14) 
#185) MeSH descriptor: [Angina Pectoris] explode all trees (4571) 
#186) Angor Pectoris  (55) 
#187) Stenocardia  (59) 
#188) MeSH descriptor: [Coronary Disease] explode all trees (13453) 
#189) Coronary Heart Disease  (18614) 
#190) MeSH descriptor: [Myocardial Infarction] explode all trees (10984) 
#191) Cardiovascular Stroke  (9658) 
#192) Heart Attack  (2573) 
#193) Myocardial Infarct  (2952) 
#194) MeSH descriptor: [Stroke] explode all trees (8879) 
#195 Apoplexy  (418) 
#196) CVA (Cerebrovascular Accident)  (322) 
#197) Cerebral Stroke   (10598) 
#198) Cerebrovascular Accident  (8350) 
#199) Acute Cerebrovascular Accident  (2528) 
#200) Cerebrovascular Apoplexy  (134) 
#201) Cerebrovascular Stroke  (12133) 
#202) Acute Stroke  (13691) 
#203) Brain Vascular Accident  (609) 
#204) MeSH descriptor: [Thrombosis] explode all trees     (4884) 
#205) Blood Clot  (2170) 
#206) Thrombus  (2017) 
#207) MeSH descriptor: [Thromboembolism] explode all trees  (2307) 
#208) MeSH descriptor: [Hemorrhage] explode all trees (13859) 
#209) Bleeding  (32697) 
#210) MeSH descriptor: [Arteriosclerosis] explode all trees (9322) 
#211) MeSH descriptor: [Angioplasty] explode all trees     (4891) 
#212) Transluminal Angioplasty  (2513) 
#213) Endoluminal Repair  (38) 
#214) Percutaneous Transluminal Angioplasty    (2291) 
#215) MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees (5372) 
#216) Percutaneous Coronary Revascularization  (3025) 
#217) MeSH descriptor: [Stents] explode all trees (4756) 
#218) #175 or #176 or #177 or #178 or #179 or #180 or #181 or #182 or #183 or #184 or #185 or #186 or 
#187 or #188 or #189 or #190 or #191 or #192 or #193 or #194 or #195 or #196 or #197 or #198 or #199 or #200 
or #201 or #202 or #203 or #204 or #205 or #206 or #207 or #208 or #209 or #210 or #211 or #212 or #213 or 
#214 or #215 or #216 or #217    (120155) 






4) Clinicaltrials.gov Expert search (Search results – 141 studies) 
INFLECT EXACT NOT NOTEXT [RESULTS-FIRST-SUBMITTED] AND ( atrial 
fibrillation OR acute coronary syndrome OR percutaneous coronary intervention OR atrial 
flutter OR myocardial ischemia OR angina pectoris OR coronary disease OR myocardial 
infarction OR angioplasty OR stents OR coronary artery disease ) [DISEASE] AND ( 
Antiplatelet Drug OR oral anticoagulant OR aspirin OR Acetylsalicylic Acid OR ASA OR 
Acetysal OR Acylpyrin OR Aloxiprimum OR Colfarit OR Dispril OR Easprin OR Ecotrin 
OR Endosprin OR Magnecyl OR Micristin OR Polopirin OR Polopiryna OR Solprin OR 
Solupsan OR Zorprin OR dipyridamole OR Antistenocardin OR Apo-Dipyridamole OR 
Cerebrovase OR Cleridium OR Curantil OR Curantyl OR Kurantil OR Miosen OR Novo-
Dipiradol OR Persantin OR Persantine OR triflusal OR Disgren OR clopidogrel OR 
clopidogrel napadisilate OR clopidogrel OR Iscover OR PCR 4099 OR PCR-4099OR 
clopidogrel-Mepha OR SC 25989C OR SC 25990C OR SR 25989 OR clopidogrel besylate 
OR clopidogrel besilate OR clopidogrel hydrochloride OR clopidogrel Sandoz OR 
clopidogrel bisulfate OR Plavix OR Prasugrel Hydrochloride OR Prasugrel HCl OR Prasugrel 
OR CS 747 OR CS-747 OR LY 640315 OR LY-640315 OR LY640315 OR Effient OR 
Efient OR Ticagrelor OR AZD 6140 OR AZD-6140 OR AZD6140 OR Brilinta OR Brilique 
OR Ticlopidine OR Ticlopidine Hydrochloride OR Ticlodix OR Ticlodone OR Ticlid OR 53-
32C OR 53 32C OR 5332C OR cilostazol OR OPC 13013 OR OPC-13013 OR Pletal OR 
vorapaxar OR Zontivity OR SCH 530348 OR SCH530348 OR SCH-530348 OR abciximab 
OR c7E3 Fab OR chimeric 7E3 Fab OR Clotinab OR ReoPro OR CentoRx OR eptifibatide 
OR epifibatide OR epifibratide OR Integrilin OR Integrelin OR tirofiban OR MK 383 OR 
MK-383 OR tirofiban hydrochloride OR tirofiban hydrochloride monohydrate OR Aggrastat 
OR Agrastat OR L 700462 OR L-700462 OR L-700,462 OR cangrelor OR Kengreal OR AR 
C69931MX OR AR-C69931MX OR Platelet Aggregation Inhibitors OR Platelet 
Antiaggregants OR Antiplatelet Agents OR Antiplatelet Drugs OR Blood Platelet 
Aggregation Inhibitors OR Blood Platelet Antagonists OR Blood Platelet Antiaggregants OR 
Platelet Antagonists OR Platelet Inhibitors OR Purinergic P2Y Receptor Antagonists OR 
ADP Receptor Antagonists OR ADP Receptor Blockers OR Adenosine Diphosphate Receptor 
Antagonists OR P2Y Purinoceptor Antagonists OR P2Y1 Purinoceptor Antagonists OR 
P2Y12 Purinoceptor Antagonists OR P2Y12 Receptor Antagonists OR Purinergic P2Y12 
Receptor Antagonists OR Rivaroxaban OR Xarelto OR BAY 59-7939 OR BAY 59 7939 OR 
BAY 597939 OR Dabigatran OR BIBR 953 OR BIBR 1048 OR Dabigatran Etexilate OR 
Dabigatran Etexilate Mesylate OR Pradaxa OR apixaban OR BMS 562247 OR BMS562247 
OR BMS-562247 OR edoxaban OR DU-176b OR DU-176 OR edoxaban tosylate OR 
betrixaban OR BEVYXXA OR PRT054021 ) [TREATMENT] AND ( hemmorhage OR 
bleeding OR stroke OR thrombosis OR thromboembolism ) [OUTCOME] AND INFLECT 
EXACT ( "Adult" OR "Older Adult" ) [AGE-GROUP]  
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DATA EXTRACTION FORM  
 
IDENTIFICATION                                                                                                                                                                                                                               
Title & study ID:  
Ref number:                                                                                                                                                                                                                   
First author – year of publication:  
Study location - Worldwide 
 





Antiplatelet –  
 
Anticoagulant –  
Antiplatelet -  
 
Number of patients / sample size                                                     
        
          Age  
 
       Mean    
65 - 74 years   
 ≥ 75 years   
                  Female — no. (%)   
                  Male — no. (%)   
                 HAS-BLED score    
            CHA2DS2-VASc score   
      Creatinine clearance – ml/min   
Comorbidity 
(%):        
                                           
                              
                              
                              
                                 
  Atrial fibrillation           
Acute coronary syndrome   
 Coronary artery disease   
         Recent MI    




Aspirin   
     P2Y12 inhibitor   
          Prior VKA use   
  NOAC   
Proton pump inhibitor            
                  NSAID 
 
  
Type of stent 
(%):           
                                                    
                         
Drug eluting stent   
Bare metal stent   
Drug-eluting & bare-metal 
stents 
  










Was the study described as randomized (this included such words as « randomly », 
« random » or « randomization » 
    /1 
Was the method used to generate the sequence of randomization described and was 
it appropriate (e.g table of random numbers, computer-generated) 
    /1 
Was the study described as double-blind?     /1 
Was the method of double-blinding described and was it appropriate (e.g identical 
placebo, active placebo, dummy)? 
    /1 
Was there a description of withdrawals and dropouts?     /1 
Deduct 1 point if the method used to generate the sequence of randomization was 
described but was inappropriate (e.g. patient were allocated alternatively or according 
to date of birth of hospital number) 
 /-1 
Deduct 1 point if the study was described as double-blind but the method of blinding 
was inappropriate (e.g. comparison of tablet vs. Injection with no double dummy) 
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Sensitivity analysis and Publication bias 
 
Figure S1: One way sensitivity analysis for the safety outcome of major bleeding for DOAC with / 
without concomitant antiplatelet therapy in AF 
 
 
Figure S1p: Evaluation of publication bias using a funnel plot  
 
 
















MH log odds ratio
Funnel Plot of Standard Error by MH log odds ratio
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Figure S2: One way sensitivity analysis for the efficacy outcome of MACE for DOAC with / without 




Figure S2p: Evaluation of publication bias using a funnel plot 
 
 
















MH log odds ratio
Funnel Plot of Standard Error by MH log odds ratio
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Figure S3: One way sensitivity analysis for the efficacy outcome of stroke or SE for DOAC with / 


























Funnel Plot of Standard Error by Log odds ratio
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Figure S4a: One way sensitivity analysis for the efficacy outcome of MI for DOAC with / without 


























MH log odds ratio
Funnel Plot of Standard Error by MH log odds ratio
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Figure S4b: One way sensitivity analysis for the efficacy outcome of MI for DOAC with / without 














Favours DOAC + Antiplatelet        Favours DOAC     
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Figure S5: One way sensitivity analysis for the efficacy outcome of vascular death with / without 
concomitant antiplatelet therapy in AF  
 
















MH log odds ratio
Funnel Plot of Standard Error by MH log odds ratio
Figure S5p: Evaluation of publication bias using a funnel plot 
